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Abstract 
 
 
 
Vaccinia virus (VV), a member of the poxvirus family of double-stranded DNA 
viruses, is well-known as a highly effective vaccine against variola virus, the causative 
agent of smallpox.  Poxviruses encode many strategies to evade the host immune and 
anti-viral response.  One such host anti-viral response, activation of the double-stranded 
RNA activated protein kinase (PKR) pathway, is important in sensing the presence of 
intracellular viral genomes and their products.  PKR is activated by dsRNA, a by-product 
of many virus infections, and exhibits its anti-viral effects in part via inhibition of protein 
synthesis and activation of the pro-inflammatory transcription factor NF-κB.  I have 
identified the vaccinia virus K1 protein as an inhibitor of PKR activation.  I determined 
that the C-terminal portion of the 2nd ankyrin repeat, a motif important for protein-protein 
interactions, is important for this inhibitory function.  Further, K1 mediated PKR 
inhibition also blocks activation of downstream NF-κB in VV infected cells.   
 Previous characterization of the K1 protein identified it as a host-range protein 
required for a productive infection.  When the K1L gene is absent, replication is aborted 
due to shut-down in viral protein synthesis.  I queried whether PKR was responsible for 
this effect.  I found that replication when K1 was lacking could not be rescued by 
depletion of PKR protein levels.  Hence K1 inhibition of PKR is not related to the host-
range function. 
 I next identified that the trigger for PKR activation is viral dsRNAs derived from 
early or intermediate viral transcription.  As early dsRNAs have never been reported 
during a poxvirus infection, this finding was novel.  Further, I found that there were 
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higher levels of dsRNA present during a VV infection when K1 was absent or mutated.  
Finally, ectopic expression of K1 was able to inhibit PKR activation induced by viral 
dsRNAs.  Together these data identifies a new function for the K1 protein and elucidates 
a strategy viruses utilize to inhibit detrimental host cell responses.  
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Chapter 1: Introduction 
 
 
 
1) Poxvirus Overview 
 Poxviruses are large, complex viruses capable of infecting a wide range of 
vertebrate and invertebrate hosts.  In the Poxviridae family there is considerable diversity 
amongst species in terms of pathogenesis and host-range (ability to infect different hosts).  
Major unifying characteristics amongst all of the viruses in this family include; (1) the 
ability to replicate exclusively in the cytoplasm of the host cell (2) coding capacity for 
enzymes involved in viral DNA replication and transcription and (3) a large, linear 
double-stranded DNA genome ranging from 130-300 kbp in size [51, 64]. 
 
Structure and morphology. 
 Poxviruses have a characteristic brick-shaped morphology and are typically 200 
nm in height by 300 nm in length.  The large size of poxviruses allows them to be viewed 
with a light microscope, a unique feature of poxviruses.  Transmission electron 
microscopy studies have revealed that mature virions are wrapped in either a single or 
double membrane depending upon the method of virus release and have a dumbbell 
shaped core housing the genome, with two lateral bodies flanking the core [64]. 
 
Classification. 
 The Poxiviridae family has two subfamilies: Entomopoxvirinae and 
Chordopoxvirinae whose members infect insects and vertebrates, respectively.  The 
Chordopoxvirinae subfamily is of public health interest as it contains members of the 
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Orthopoxvirus and Molluscipoxvirus genera, which contain virus species that cause 
disease in humans.  The Orthopoxviruses are the best characterized viruses, as this genus 
contains the clinically relevant species monkeypox virus, cowpox virus, vaccinia virus 
(VV) and variola virus (VARV).  VV is considered the protypical poxvirus and is used as 
a model for many different aspects of poxvirus biology.  VV is best known as the vaccine 
responsible for the eradication of smallpox, a disease caused by variola virus.  The 
efficacy of the vaccine was due to the genetic and antigenic similarity between VV and 
the more pathogenic VARV.  Thus, infection with VV provides cross-protective 
immunity against VARV [64].  Molluscum contagiosum virus (MCV) is the only 
member of the Molluscipoxvirus genus and exclusively infects humans [7]. 
 The complete genome sequences of 110 poxviruses are known.  There are 49 
common genes within the sequenced members of the Poxviridae.  Within the 
Chordopoxvirinae subfamily, there are 90 conserved genes, most of which function in 
basic viral processes such as replication, transcription and virion assembly [51].  For 
most poxviruses, these genes in common are localized towards the center of the viral 
genome.  The greatest genetic diversity amongst poxvirus species occurs at the terminal 
ends of the genome.  Genes located at the terminal ends typically encode proteins that 
regulate virus-host interactions or interfere with host cell anti-viral signaling.  These 
genes are often referred to as host-range genes if they confer the ability to replicate in a 
given host or immunoevasion/immunomodulatory proteins if they interfere with host 
immune response signaling pathways [51, 67].  As these proteins typically function as 
virulence factors, understanding of how they function can provide insight into vaccine 
and drug development and pathogenesis of poxvirus diseases. 
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Relevance for studying poxviruses. 
 VARV killed more people than all other infectious agents combined over the 
course of recorded history.  While the World Health Organization (WHO) declared 
smallpox eradicated in 1980, VARV remains a global bioterrorism concern.  There are 
only two WHO approved VARV frozen stocks in existence, but fears have increased that 
they are not the only remaining ones.  With the cessation of smallpox vaccination in the 
1980s, a large percentage of the world population is now susceptible to smallpox.  Due to 
the potentially catastrophic effects of deliberate release of smallpox, much research and 
funding is aimed at producing safer vaccines [57].   
 While VARV is certainly the most notorious poxvirus, there are other poxviruses 
that can cause serious disease in humans.  An outbreak of human monkeypox, caused by 
the monkeypox virus, occurred in the mid-western United States in 2003.  The outbreak 
was eventually traced back to a shipment of rodents from western Africa where 
monkeypox is endemic.  Fortunately, the strain responsible for the outbreak was the less 
pathogenic West African strain of monkeypox virus, which is less pathogenic than the 
central African variant [57].  Outbreaks of VV in Brazilian dairy cattle workers have 
been reported since the 1960s, presenting as lesions on the hands, arms and faces of 
infected individuals [20, 90].  Such outbreaks highlight the impact of poxviruses on 
public health and the need for continued research. 
 Finally, poxviruses are currently being exploited for their potential as oncolytic 
viruses.  Oncolytic viruses are recombinant viruses engineered to selectively infect and 
kill cancer cells.  Poxviruses are attractive for this application for the following reasons; 
1) their large genome size allows for ease of genetic manipulation, 2) they can infect a 
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broad range of cell types, 3) they replicate and kill cells quickly and 4) they elicit a strong 
immune response to aid in killing of the target tumor cells [46].  Due to the threat to 
public health and the potential for their therapeutic use, continued poxvirus research is 
essential. 
  
2) Pathogenesis of Poxvirus Disease 
 The route of entry into the host differs amongst poxviruses and includes entry via 
the respiratory tract and skin.  VARV infection in humans was spread mainly via the 
respiratory route from aerosolized secretions of infected individuals.  Infection via the 
respiratory route resulted in 30-40% case fatality in contrast to 1-2% when virus 
inoculation or “variolation” occurred subcutaneously [27, 44].   
The model for generalized poxvirus infection and pathogenesis is based on studies 
with ectromelia virus, a closely related virus to VARV that infects mice and results in a 
smallpox-like disease [28].  This model also closely predicts rabbitpox and monkeypox 
infections [29].  Based on this model, upon entry into the host, the virus replicates in 
macrophage and is disseminated via the host lymphatic and circulatory systems primarily 
by infected leukocytes.  At approximately 3-4 days post-infection the virus reaches 
secondary organs such as the bone marrow, spleen and liver where it continues to 
replicate and produces the primary viremia.  At approximately 5 days post-infection the 
virus is released from the organs into the blood producing a secondary viremia and the 
virus is eventually present in most tissues including the skin by 9 days post-infection.  
Pock lesions will form within a few days after that [28].  The lesions are typically raised 
and pustular; the rash is the most commonly recognized feature of a smallpox infection.  
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In some individuals, uncontrolled virus replication resulted in death even before lesions 
appeared on the skin [84].  In addition to the direct damage caused by the virus to the 
cells and tissues, recent focus has been placed on the pathological side effects of the host 
response.   Overproduction of inflammatory cytokines has been shown to lead to septic 
shock.  Indeed many of the symptoms associated with poxvirus infection are similar to 
those observed during infection with viruses that produce a “cytokine storm” leading to 
uncontrolled inflammation and sepsis [52].   
In contrast to VARV, cowpox virus and VV primarily enter the host through skin 
abrasions.  The virus replicates in dendritic cells at the inoculation site and produces a 
primary skin lesion.  In healthy individuals, the virus is typically cleared and an antibody 
response mounted against the virus.  Administration of the smallpox vaccine is performed 
via scratching of the skin with a bifurcated needle inoculated with VV and typically only 
produces a localized lesion conferring immunity to VARV.  In immunocompromised 
individuals the primary infection can lead to systemic infection and rash as described 
above for VARV [13].   
 
3) Poxvirus Life Cycle 
 
Attachment. 
 At the start of the infectious cycle, the poxvirus virion first attaches to and enters 
the host target cell (see Figure 1.1).  The mechanism used by poxviruses to enter the host 
cell is highly debated.  To date, no cellular receptor has been identified as necessary for 
poxvirus attachment, which is in contrast to other viruses in which the mechanism has 
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been well characterized.  Due to the broad host-range of poxviruses, it is thought that the 
receptor or mechanism of entry must be ubiquitous [64].  Recent work investigating the 
possible role of glycosaminoglycans (GAGs) in virus entry revealed that the virus binds 
to cell surface GAGs, but only in some cell types [14]. 
 
Entry. 
 Using VV as a model, a great deal of work has been performed to elucidate the 
mechanism of poxvirus entry into the host cell.  The main entry mechanism used by VV 
is macropinocytosis.  VV associates with cell filopodia and induces cell membrane blebs 
resulting in the internalization of the virus particle in a low pH-dependent manner [60, 
88, 89].  A second entry mechanism has been described via membrane fusion, whereby 
the viral membrane fuses with the cellular plasmid membrane [1, 14].  Association with 
cholesterol-rich regions called “lipid rafts” is predicted to play an important role in this 
second model [18].  Fusion of the viral membrane is mediated by a multi-protein fusion-
entry complex composed of eight viral proteins necessary for virus entry.  It is thought 
that the mode of entry may vary depending on the virus and host cell-type [64]. Recently, 
evidence in support of VV “surfing” has been demonstrated whereby a cell infected by 
VV displays 2 viral proteins on its surface. These proteins induce actin tail formation, 
which prevents new virions from infecting the same cell and repels virions to neighboring 
cells allowing for rapid virus spread in vivo [23]. 
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Transcription, translation and replication of viral genomes. 
 Vaccinia virus has been used as the model poxvirus for studying transcription as 
much of the viral transcription machinery is conserved amongst poxviruses [12].  As 
poxviruses replicate exclusively in the cytoplasm of the host cell, they possess a complete 
early transcription system within the virus core.  Thus, the transcription of early viral 
mRNAs can begin upon entry into the cell.  The transcription machinery includes the VV 
RNA polymerase, vaccinia early transcription factors (VETF) and RNA polymerase 
associate factor (RAP94) [64]. 
Poxvirus gene expression occurs in a temporal fashion with genes being classified 
as early, intermediate or late depending upon when they are expressed during infection 
[12, 64] (see Figure 1.1).  Recent microarray data suggest that poxvirus genes may be 
better re-classified into the following categories; immediate-early, early, early/late, and 
late.  The immediate-early gene mRNAs can be detected as early as 20 minutes after 
entry of the virion into the cell and are more highly expressed than genes in the other 
classes [2]. 
Early genes typically encode proteins required for synthesis of viral DNA, 
transcription of intermediate genes or immunomodulatory and host-range factors.  Early 
gene transcription factors recognize specific A/T-rich early gene promoter sequences.  
Early gene transcription terminates downstream of the termination signal UUUUUNU 
and requires a viral termination factor [82, 83].  As a result, early mRNAs have 
homogenous ends in contrast to mRNAs made from late genes.  Following early gene 
transcription the virus core is disrupted.  The disruption process is thought to be partially 
responsible for early viral transcription termination as it interferes with early transcription 
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apparatuses [64].  A second factor mediating termination of early transcription is an 
increase in degradation of mRNAs mediated by the viral D9 and D10 proteins which 
have mRNA de-capping activity [67, 68].   
Disruption of the core is followed by replication of the viral genome, an event that 
precedes transcription of the intermediate and late genes.  For VV, DNA replication 
occurs between 1-2 hours post infection.  The current model for poxvirus DNA 
replication is a rolling hairpin strand displacement mechanism.  Briefly, a nick occurs at 
one or both ends of the genome providing a free 3’-end for addition of nucleotides by the 
replication machinery.  Due to the hairpin structures at the ends of the genome, the 
replicated DNA strand can then fold back on itself allowing for the remainder of the 
genome to be copied.  Concatamer junctions are subsequently resolved into unit length 
genomes [64].   
The intermediate class of genes is the smallest class, including only 5 genes to 
date, with 3 of those 5 genes encoding proteins needed for transcription of late genes.  
Intermediate gene transcription peaks at around 2 hours post infection and rapidly 
declines again, which may be due to an increase in turnover of mRNAs.  The requirement 
for intermediate gene transcription to occur after uncoating and DNA replication is 
thought to be due to an inaccessibility of the genome within the viral particle [64, 67] 
Finally, late mRNAs are produced following the synthesis of the late gene 
transcription factors.  Late genes encode the structural proteins that make up the virus 
particle and early transcription machinery that is packaged in the virus particle.  Unlike 
early transcripts, late gene transcripts have heterogeneous 3’-ends due to readthrough of 
the transcription termination sequence.  The terminal heterogeneity combined with the 
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fact that poxvirus genes are transcribed from both DNA strands can result in the 
formation of double-stranded RNAs particularly at late times of infection [64]. 
 
Virion assembly and release. 
 The last stages in a poxvirus infection are virion assembly and cell egress.  
Virions are assembled in distinct areas within the cell termed viral factories, which 
appear as dense regions when visualized by electron microscopy.  Mature virus particles 
are formed in these factories following the proteolytic processing of viral core/membrane 
proteins and genome packaging.  The resultant virion is called a mature virion (MV) or 
sometimes intracellular mature virion (IMV) [12, 64].  The MVs move from the virus 
factories via a microtubule dependent process and acquire a double membrane derived 
from either the trans-golgi apparatus or an endosome along the way.  These wrapped 
MVs are referred to as enveloped viruses or EVs.  Once at the periphery of the cell, the 
outer envelope of the MV fuses with the cytoplasmic membrane.  Infectious EVs can be 
disseminated by two different mechanisms.  In the first, cell-associated EVs use actin 
filaments to push away from the host cell to facilitate spread directly via cell-to-cell 
contact.  In an alternative mechanism, EVs can dissociate from the cell and are then 
termed extracellular enveloped viruses (EEVs) and can then be more widely disseminated 
than the surface attached EVs [64] (see Figure 1.1). 
 
4) Poxvirus Regulation of the Host Immune Response 
 As mentioned previously, poxviruses encode many immunomodulatory proteins 
in order to block host defenses and allow for a successful replication cycle.  Many 
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immune response pathways are targets for inhibition by poxviruses, including the Toll-
like receptor, apoptosis, interferon and PKR.   
The viral proteins can be divided into two general groups; those that act 
intracellularly and those that act extracellularly.  Within the class of proteins that act 
intracellulary are “virotransducer” proteins that act to inhibit cellular responses to virus 
infection and “virostealth” proteins that act to subvert host detection and recognition of 
the virus.  Extracellularly acting proteins are typically viromimics such as viral 
homologues of host surface receptors or viral mimics of host cytokines, chemokines and 
growth factors [62, 84, 87].  Interestingly, there is not a single known immunomodulatory 
protein shared by all poxviruses.  Instead, each virus encodes its own unique complement 
of inhibitors best suited for replication in its host species [84]. 
The immunomodulatory proteins are common targets for drug inhibition and 
vaccine development due to the essential roles they play.  Several smallpox virus vaccine 
strains have been developed that lack key immunomodulatory proteins, resulting in safer 
and less pathogenic vaccines [62, 87].  Additionally, many of these inhibitory proteins are 
being used to study signaling pathways and protein interactions in eukaryotic cells.  For 
example, recent work using a viral homologue (K3L) of a host-protein (eIF2α) has 
increased understanding of how eIF2α docks with its binding partner PKR and identified 
residues critical for this interaction [79]. 
 
5) PKR, the Double-Stranded RNA Activated Protein Kinase 
 A common target for interference by viral immunomodulatory proteins is the 
PKR (protein kinase RNA-activated) pathway.  PKR is activated by double-stranded 
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RNA (dsRNA) and is transcriptionally induced by interferons (IFNs) [31].  IFNs are 
secreted in response to a virus infection and induce a wide range of antiviral activities 
[77].  PKR is one of the IFN stimulated molecules that plays a critical role in sensing a 
viral infection and establishing an anti-viral state within the host cell [31]. 
 
PKR activation. 
PKR is a serine-threonine kinase, consisting of an N-terminal regulatory domain 
containing two dsRNA binding domains, and a C-terminal catalytic domain [61].  PKR is 
activated by binding to dsRNA, which is a byproduct of many virus infections [19].  For 
RNA viruses, dsRNA forms during replication of the virus genome.  For DNA viruses 
such as poxviruses, mRNA is encoded on both strands of DNA and hence dsRNA forms 
when overlapping mRNA transcripts hybridize to one another [19, 31].   
In non-stressed cells, PKR exists as an inactive monomer, auto-inhibited by 
intramolecular interactions between its N and C-terminal domains [19].  Upon binding to 
dsRNA, PKR undergoes a conformation change allowing homodimerization and auto-
phosphorylation at two critical threonine residues, T446 and T451 [22, 97].  The 
conformation change renders the kinase active and able to bind target substrates.  
Recognition of dsRNA by PKR requires greater than 30 base pairs of duplex RNA and 
recognition is sequence independent [74].  In addition to natural dsRNA, PKR can also be 
activated by poly I:C (a synthetic dsRNA), the cellular activator PACT and cell stress 
[70] (see Figure 1.2). 
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PKR and translation regulation. 
Once activated, PKR is an integral component of many signaling pathways 
including toll-like receptor 3 signaling [45], STAT, p58, apoptosis and NF-κB signaling 
pathways, and most-importantly, signaling to eIF2α, the eukaryotic translation initiation 
factor alpha subunit [31, 91, 94] (see Figure 1.2).  PKR is one of 4 mammalian eIF2α 
kinases, including PERK, GCN2 and HRI,  that phosphorylate eIF2α in response to 
cellular stress [93].   
The eIF2 complex, composed of α, β and γ subunits, promotes delivery of the 
initiator Met-tRNA to the 40S ribosome.  After binding of the Met-tRNAi to the initiation 
complex eIF2 is released and GTP is hydrolyzed [40, 55].  The inactive eIF2-GDP is 
recycled back to the active eIF2-GTP form by the GTP exchange factor eIF2B.  
Phosphorylation of eIF2α by PKR at serine residue 51 causes in an increase in affinity of 
eIF2 for eIF2B.  Since eIF2B is present in limited amounts, the phosphorylation inhibits 
recycling of eIF2 back to its active form and inhibits translation [85].  This mechanism of 
protein synthesis shutoff allows the host cell to establish an anti-viral state upon 
recognition of virus infection. 
 
PKR and NF-κB. 
 A second pathway activated by PKR is the NF-κB pathway.  NF-κB is a pro-
inflammatory transcription factor activated by a diverse array of stimuli such as Tumor 
Necrosis Factor (TNF), Toll-like receptor (TLR) signaling, and other cytokines [39].   
 NF-κB consists of homo- or hetero-dimers of NF-κB family member proteins 
p50, p65, Rel-B, c-Rel and p52.  p65/p50 hetero-dimers are being the most common.  
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NF-κB is regulated by interaction with inhibitory proteins in the IκB family (IκBα, IκBβ, 
IκBγ, IκBε, Bcl-3, p105 and p100) [39].  In unstimulated cells, NF-κB is retained in the 
cytoplasm due to the occlusion of the nuclear localization signal (NLS) by the IκB 
protein [91].   
In response to various stimuli such as those mentioned above, IκB proteins are 
phosphorylated by the IKK complex, a large multiprotein kinase complex consisting of 
two kinase subunits (α and β) and a regulatory subunit γ [39].  Phosphorylation of the IκB 
protein at two conserved serine residues results in ubiquitination and proteasome 
degradation, liberating the NF-κB dimer to translocate to the nucleus and upregulate 
transcription of its target genes [32, 75] (see Figure 1.3).   
 The mechanism by which PKR activates NF-κB is still under debate.  Initial in 
vitro and in vivo work indicated that in response to dsRNA, PKR phosphorylates IκBα 
directly to activate NF-κB [48].  More recent evidence suggests an indirect role for PKR 
in IκB phosphorylation instead focusing on the IKK complex as target for PKR mediated 
NF-κB activation.  The importance of the IKK complex in this pathway was confirmed 
using cell lines lacking components of the IKK complex and dominant negative 
constructs of IKK, however the mechanism by which PKR activates NF-κB remains 
unclear [8, 17, 35, 96]. 
 PKR has been shown to interact with the IKK complex, though whether this is an 
indirect or direct interaction is unclear [8, 35, 96].  PKR interaction with several members 
of the TRAF (TNF Receptor Associated Factor) family has also been shown to be 
important for signaling to NF-κB [34].  The most debated question is whether the 
catalytic activity of PKR is required for signaling to NF-κB.  A catalytically inactive 
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form of PKR was shown to still interact with the IKK complex suggesting the catalytic 
activity is not required but instead PKR may act on the IKK complex via protein-protein 
interactions [33].  Further evidence supporting this showed that only the N-terminal 
regulatory region of PKR is required for NF-κB activation [9].  In contrast, experiments 
using PKR knockout cell lines demonstrated that wild-type PKR, but not catalytically 
inactive PKR, could complement to restore PKR-mediated NF-κB activation [47].  It is 
thought that the mechanism by which PKR activates NF-κB may be cell line/type specific 
[30]. 
 
Host cell regulation of PKR. 
 Since PKR engages a variety of signaling pathways, it is no surprise that it is 
regulated by several different cellular factors in addition to its own auto-regulatory 
mechanism.  p58IPK is one of the best studied cellular inhibitor of PKR.  It binds to PKR 
and prevents dimerization and activation [50].  Other cellular inhibitors include the 
glycoprotein p67, chaperones Hsp90 and Hsp70 and nucleophosmin (NPM) [21, 24, 36, 
66]. 
 In addition to inhibitors of PKR, there are several cellular activators of PKR.  The 
human PACT and its mouse orthologue RAX are two activators of PKR [42, 70].  
Triggered by cellular stress including dsRNA, PACT/RAX becomes phosphorylated and 
binds to PKR to activate it [6, 72].  Mda-7 (melanoma differentiation-associated gene-7) 
interacts with and activates PKR when overexpressed, and E2F-1 can induce PKR 
expression and autophosphorylation [69, 92]. 
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Viral inhibitors of PKR. 
A tribute to the importance of PKR in defending against a virus infection is the 
fact that many viruses, including VV, possess strategies to inhibit PKR activation.  The 
inhibitors act at many different stages in the PKR activation pathway.  Commonly used 
inhibitory strategies include: sequestering dsRNA, inhibiting PKR dimerization, encoding 
PKR pseudosubstrates or eIF2α phosphatases, and degrading PKR [30].  PKR inhibitory 
strategies are encoded by both DNA and RNA viruses including viruses in the herpes, 
hepatitis, influenza and retrovirus families. 
Vaccinia virus encodes three inhibitors of the PKR pathway, E3, K3 and K1, 
which are the focus of this thesis work [5, 15, 95].  Due to the large coding capacity of 
poxviruses it is not uncommon for multiple immunomodulatory proteins to target the 
same pathway.  Usually viral inhibitors of the same signaling pathway will work at 
different stages, thereby ensuring inhibition from a variety of activators and blocking 
crosstalk from other pathways.  The VV E3 protein possesses a dsRNA binding motif and 
sequesters dsRNA to prevent PKR activation, which is required for replication of VV in a 
wide range of host cells and for pathogenesis in a mouse model [4, 11].  In addition to 
binding dsRNA, E3 has also been shown to bind to PKR directly to inhibit its activation 
[76].  The VV K3 protein has homology to eIF2α and acts as a pseudosubtrate to inhibit 
PKR activity [5].  K3 has been shown to inhibit activation of PKR by binding to PKR 
directly at the same site as PKR binds to eIF2α [49, 79, 80].   
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6) The VV K1 Protein 
 
The K1L gene and protein structural motifs. 
 The VV K1L gene encodes a 30-kDa protein in the immediate early class of genes 
[2].  The gene designation resulted from a HindIII digest of the vaccinia virus genome, in 
which the fragments were given letter designations A-O.  Within each fragment ORFs 
were numbered and given the designation L if the gene was transcribed in a left-ward 
orientation or R if the gene was transcribed in the right-ward orientation.  Hence the K1L 
gene is the first ORF in the K fragment and transcribed in the left-ward orientation [37].   
The only structural motifs present in the K1 protein are 9 ankyrin repeats (ANKs) 
which are approximately 33-residue motifs that mediate protein-protein interactions.  
ANKs are found in a diverse array of proteins of both cellular and viral origin and form a 
structural scaffold for interaction with other proteins [63, 78].  Each repeat consists of a 
β–hairpin, two antiparallel α–helices and a connecting loop.  Repeats stack together via 
hydrophobic interactions to form an L-shaped structure with a solvent exposed 
interaction surface.  While the structure of the ANK repeat is conserved amongst 
different ANK containing proteins, the residues in the surface exposed region differ to 
mediate binding specificity with the target protein [78].  The importance of the K1 ANK 
repeats has recently been investigated and will be discussed in detail in a following 
section.   
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The K1 host-range function. 
 K1 was one of the first poxvirus proteins identified as a host-range protein 
required for replication in mammalian cells.  Early experiments identified strains of VV 
that were defective for replication in human cells and these strains were shown to have 
undergone spontaneous gene deletions [26].  The K1L gene was later found to be one of 
the genes deleted in these strains [26, 37, 71].  Further characterization of the replication 
defect of K1L- viruses revealed that replication is halted at the stage of early viral protein 
synthesis in rabbit kidney RK13 cells and intermediate viral protein synthesis in human 
cell lines [41, 73, 86].  Replication of a K1L- virus was also shown to be complemented 
by stable expression of the K1 protein in the host cell line [86].  Interestingly, while early 
viral RNA transcripts are produced and then disappear by 3 hours after infection of RK13 
cells with a wild-type virus, infection with a K1L- virus results in early viral mRNA 
production that is stably detected for at least 6 hours post-infection [73]. 
 Two other poxvirus proteins, the VV C7 protein and cowpox virus CP77 protein 
can complement a K1L- virus and restore the ability of the virus to replicate.  In human 
cells either the K1 or the C7 protein are required for a productive infection, as a double 
knockout K1L-C7L- virus is unable to replicate while single knockout viruses for either 
gene are replication competent.  In RK13 cells, K1 is required and expression of C7 does 
not complement for K1 [38, 71].  Unlike C7, the CP77 protein is able to complement for 
K1 in either rabbit or human cell lines.  Studies in RK13 cells with a K1L-CP77+ virus 
revealed that although CP77 can complement for K1, the mechanism of action of CP77 is 
distinct from that of K1 [73].  
  
 18 
K1 inhibition of NF-κB activation. 
 In addition to the host-range function of K1, the Shisler lab published that the K1 
protein inhibits the pro-inflammatory NF-κB pathway (described in section 5C).  Briefly, 
infection of RK13 cells with a K1L- virus results in NF-κB activation as measured by 
NF-κB reporter luciferase activity.  Expression of K1 was found to be both necessary and 
sufficient to inhibit NF-κB activation and degradation of its inhibitory protein IκBα [81]. 
 
K1 interacting proteins. 
 Based on the fact that K1 has ANK repeats, it is predicted to bind target protein/s.  
Three proteins have thus far been shown to bind to K1.  The first is the VV C10 protein 
which has been shown to bind K1 via a yeast two hybrid assay.  The function of the C10 
protein is unknown [56].  The rabbit homologue of the human ACAP2, a GTPase-
activating protein for the small GTPase ARF6, has also been shown to bind to K1, though 
this interaction is not important for the host-range function of K1 [10, 43, 58].  Finally, 
K1 has been reported to bind to ERK5, a mitogen activated protein kinase (MAPK) 
(unpublished data, personal communication with Dr.  Yan Xiang, University of Texas-
San Antonio). 
 
Analysis of K1 ANK repeats. 
 Recent publications have examined the importance of the K1 ANK repeats in 
relation to the K1 host-range effect.  A series of mutant K1L genes were inserted into a 
C7L- parental background allowing for study of K1 ANK repeats in both human and 
RK13 cells.  ANK deletion and substitution mutations within the K1L gene were made 
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containing a synthetic ANK sequence predicted to maintain the ANK structure, but alter 
residues predicted to be important for K1 protein-protein interactions.  The mutants were 
assayed for their ability to replicate in RK13 and HeLa cells.  Interestingly, the 
importance of different ANK repeats was cell-type specific.  In RK13 cells, only ANK4 
and 6 can be mutated without affecting replication while in HeLa cells only ANK1, and 
the C-terminal portions of ANKs 2 and 3 are important for virus replication [58].  The 
results indicate that different regions of the K1 protein are required for interactions with 
the target protein depending upon the cell type. 
 More recently, the crystal structure of K1 was solved, which revealed that while 
computer modeling and sequence alignments predict K1 to have 6 ANK  repeats, K1 
actually contains 7 full ANK repeats and 2 partial ANK repeats at the C and N-termini of 
the protein.  Two residues (Phe82 and Ser83) shown to be critical for replication were 
found to be surface expressed on the opposite side (convex side) of the predicted 
interaction domain.  These results suggest that K1 may use an interaction strategy 
dinstinct from other ANK containing proteins described thus far [53]. 
 
Functions of the CP77 and C7 proteins. 
 As the CP77 and C7 proteins complement for the K1 host-range defect, it is 
pertinent to consider the functions of these two proteins as K1 may act in a similar 
manner.  The CP77 protein was first recognized as a protein required for VV replication 
in Chinese hamster ovary CHO-K1 cells.  Vaccinia replication is abortive in CHO cells 
and insertion of the CP77 gene into the vaccinia genome allows for a productive infection 
[25, 71].  Like K1, CP77 also contains ANK repeats though the two share no homology 
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other than this structural motif.  In addition to the host-range function, CP77 has been 
shown to inhibit PKR activation.  While suppression of PKR activation partially relieves 
the host-range block during replication of a CP77- virus, it is not sufficient to restore 
replication to wild type levels [41].  Finally, CP77 has been demonstrated to inhibit NF-
κB activation independent of the host-range function [16].  Recent work has shown that 
NF-κB activation induced by an attenuated VV strain, occurs via the PKR pathway and 
activation of NF-κB can be blocked by inserting either the K1 or CP77 genes into the 
genome [54].  Indeed, my thesis work has demonstrated a similar conclusion for the K1 
protein.   
The CP77 protein has been much better studied than the C7 protein, though like 
CP77, C7 has recently been shown to inhibit PKR activation [3, 65].  Additional work 
has suggested that C7 and K1 may play a role in antagonizing the antiviral activities 
induced by type I IFNs and this function is related to the host-range effects [59].  Given 
that the CP77 and C7 proteins inhibit PKR activation it seemed plausible that K1 may 
also inhibit the PKR pathway.  An attractive hypothesis is that K1 inhibits PKR 
activation in order to (1) inhibit NF-κB activation and (2) inhibit eIF2α phosphorylation 
in order to block shutoff of protein synthesis and allow for a productive infection.  The 
testing of this hypothesis has been the focus of my thesis work. 
 
7) Thesis Outline 
 Though the K1 host-range function was first described in 1981, no mechanism for 
the K1 mode of action or any other functions, had been described until the Shisler lab 
published that K1 inhibits NF-κB activation in 2004 [81].  The goal of my thesis project 
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was to characterize how K1 inhibits NF-κB activation, which we hypothesized was via 
inhibition of the PKR pathway.   
  Chapter 2 details the discovery of a novel function for the K1 protein in 
inhibition of PKR activation.   I showed that mutant forms of K1 unable to support 
replication were also unable to block PKR activation.  Further, I demonstrated that 
depletion of PKR protein from cells blocked virus induced phosphorylation of the 
downstream target eIF2α.  Finally, I hypothesized that K1 inhibition of PKR was 
responsible for mediating a productive infection.  However, silencing of PKR did not 
rescue viral protein synthesis or replication. 
 Chapter 3 details studies examining the source of PKR activation during a K1L- 
infection.  Experiments using inhibitors of different stages of the virus life cycle revealed 
that PKR activation occurs during early viral transcription in RK13 cells and intermediate 
viral transcription in HeLa cells.  Further studies showed that these RNAs were double-
stranded in nature and accumulated at the early phase of infection in RK13 cells and the 
intermediate phase of infection in HeLa cells during infection with a K1L- virus.  As 
further proof of K1 inhibition of PKR, I demonstrated that ectopic expression of K1 can 
inhibit PKR activation induced by either Poly I:C or viral dsRNAs.  Finally, I found that 
K1 inhibition of NF-κB activation, an event downstream of PKR activation, was 
dependent upon PKR as silencing of PKR protein expression blocked NF- κB activation 
during infection with a VV strain lacking K1. 
Chapter 4 discusses attempts to find binding partners for K1 including the p65 
NF-κB protein and the PKR protein.  In addition, chapter 5 describes the discovery of 2 
additional rabbit cell lines (LLC-RK1 and R9AB) for which K1 is required for 
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replication, inhibition of NF-κB activation and inhibition of eIF2α phosphorylation.  
Lastly, the role of K1 in stimulation of translation was briefly assessed in relation to the 
host-range function of K1.  
 While the initial goal of my thesis project was to determine the mechanism by 
which K1 inhibits NF-κB activation, the outcome of my studies revealed not only that K1 
inhibits PKR activation but also sheds light on the basic biology of a poxvirus infection.  
While dsRNAs have been previously reported to form at intermediate and late stages of 
VV infection, there have been no previous reports of dsRNAs forming during the early 
phase of VV infection.  This is a novel and exciting finding within the poxvirus field. 
Understanding how viral immunomodulatory proteins such as K1 function can 
lead to the production of safer vaccines and more effective anti-viral therapies. Many of 
the VV vaccine strains that have been developed lack host-range and immunomodulatory 
genes such as K1. Determination of the function of these proteins and how they perturb 
signaling pathways during infection leads to better understanding of the host generated 
immune response.   
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8) Figures 
 
 
Figure 1.1 Poxvirus replication cycle (adapted from Harrison, 2004). Upon binding 
and entry into the host cell, early viral mRNAs and proteins are made (shown in green). 
Next, uncoating and replication of the viral genome occur followed by intermediate (red) 
and late (black) transcription and translation.  Virus particles are assembled and 
morphogenesis results in the release of EEV (extracellular enveloped virus) which can 
spread to infect a neighboring cell. Please see the text for more detail. 
 24 
 
Figure 1.2 PKR activation. Both RNA and DNA viruses are known to produce dsRNA 
intermediates during the virus life cycle. Monomeric PKR exists in the cytoplasm in an 
inactive state. Upon formation of dsRNA intermediates, PKR binds to dsRNA triggering 
its dimerization and auto-phosphorylation. Once phosphorylated, PKR is an active kinase 
and can trigger phosphorylation of eIF2α resulting in a halt in translation and nuclear 
translocation of the pro-inflammatory transcription factor NF-κB. Both of these events 
help to establish an anti-viral state to hinder virus replication. In addition to viral dsRNA, 
PKR can be activated by cellular activators PACT/RAX, synthetic dsRNA, Poly I:C and 
general cell stress. 
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Figure 1.3 The NF-κB activation pathway. Activation of NF-kB via signals such as 
stress, infection, cytokines and dsRNA induces phosphorylation and activation of the 
IKK complex by a number of different kinases. The active IKK complex then 
phosphorylates the inhibitory protein, IkBα. Next, IkBa is ubiquitinated and degraded by 
the 26S proteosome. Freed NF-kB heterodimers translocate to the nucleus and NF-kB 
stimulates transcription of its target genes. 
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Chapter 2: The effect of the vaccinia K1 protein on the PKR-eIF2α pathway in 
RK13 and HeLa cells 
 
 
 
Note: The results included in this chapter were published previously [29].  
1) Introduction 
Vaccinia virus, a member of the Poxviridae family, has historically been used as a 
vaccine to protect against smallpox, a disease caused by the closely related variola virus 
[13].  Like all poxviruses, vaccinia virus is a complex virus that codes for approximately 
200 proteins [13].  Unique to this family of DNA viruses is a replication cycle that occurs 
in the cytoplasm of its host cell.  As such, poxviruses produce many proteins to alter the 
cellular environment to allow for viral gene expression, DNA replication and 
morphogenesis [13].  Identification of such mechanisms gives insight into the cellular 
anti-viral responses that must be inactivated for a productive infection. 
The down-regulation of protein synthesis is a powerful cellular mechanism to 
prevent virus replication.  One such protein to mediate this event is eukaryotic translation 
initiation factor 2 (eIF2α)[17].  In normal cells, eIF2α is unphosphorylated.  Cellular 
proteins identified to phosphorylate eIF2α include PKR, PERK, GCN2 and HRI [17].  
Once eIF2α is phosphorylated on serine residue 51, eIF2α prevents translation initiation, 
resulting in a dramatic decrease in protein synthesis [17].   
In virus-infected cells, PKR is commonly the mediator of eIF2α phosphorylation 
[6].  To inhibit this antiviral response, poxviruses encode proteins that inhibit the PKR-
eIF2α phosphorylation pathway.  For example, the vaccinia virus E3 protein binds to 
dsRNA or to PKR to prevent PKR activation [19, 20, 22, 25].  The cowpox virus CP77 
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(CHOhr) protein also inhibits PKR activation during poxvirus infection [9].  Because, 
CP77 lacks RNA binding domains, it likely utilizes an inhibitory mechanism distinct 
from the E3 mechanism.  Yet another vaccinia protein, C7, prevents PKR 
phosphorylation [12], thereby inhibiting eIF2α phosphorylation [14]. 
Poxviruses possess host-range genes, a family of genes whose products are 
necessary for a productive virus infection[28].  The vaccinia virus K1 protein is one such 
host-range factor [15].  Infection of rabbit kidney epithelial RK-13 cells in the absence of 
the K1L ORF results in rapid inhibition of viral and cellular protein synthesis.  The 
cowpox virus CP77 protein, another host-range product, is a functional homolog of K1L, 
and substitutes for the K1 protein to restore vaccinia virus replication in RK13 cells [18].  
For human cells, such as the human cervical HeLa cell line, the K1L ORF is also required 
for virus replication [15].  In contrast to RK13 cells, either the non-homologous vaccinia 
C7L or the cowpox CP77 ORFs can substitute for the K1L ORF to allow for a productive 
infection in HeLa cells [15].   
How the K1, C7 and CP77 host-range molecules create an environment conducive 
for virus replication is unclear.  An attractive hypothesis is that these proteins prevent 
PKR activation to allow for viral protein synthesis and viral production.  However, the 
CP77 protein’s function to inhibit PKR activation does not completely rescue virus 
replication [9], suggesting that additional mechanisms are required to ensure virus 
replication.  It was unknown if the K1 protein, like other host-range proteins, affected 
PKR activation and if such a function was responsible for its host-range function.  To test 
this, the effect of the K1 protein on eIF2α phosphorylation was assessed during virus 
infection, under conditions in which the K1 protein was required for replication in RK13 
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and HeLa cells.  Using this strategy, we identified a novel eIF2α inhibitory function for 
the K1 protein.  Further analysis showed that PKR activation was responsible for eIF2α 
phosphorylation during vaccinia infection, with the K1 protein inhibiting PKR activation 
as its mechanism for function.  PKR down-regulation partially restored viral protein 
synthesis, but did not allow for plaque formation.  Thus, PKR activation may be one of 
many cellular factors responsible for inhibiting viral protein synthesis. 
 
2) Materials and Methods 
 
Cells and viruses.   
Human cervical carcinoma HeLa or rabbit kidney epithelial (RK13) cells were 
obtained from the American Type Culture Collection.  RK13 cells stably expressing the 
vaccinia E3L product (RK13-E3L) were obtained from Dr. Bertram Jacobs (Department 
of Microbiology, Arizona State University).  HeLa cells in which more than 95% of PKR 
is stably knocked down (PKRkd) were obtained from Dr. Charles Samuel (Department of 
Molecular, Cellular and Developmental Biology, University of California, Santa Barbara) 
[31].  These cells stably express a short hairpin RNA specific for PKR mRNA.  All cell 
lines were maintained in DMEM containing 10% fetal calf serum (FCS).  PKRkd cells 
were maintained in medium supplemented with 1 μg/ml puromycin (Sigma Aldrich).   
The wild-type Western Reserve strain [8] of vaccinia virus and the attenuated 
modified vaccinia Ankara (MVA) strain were used in these studies.  Virus construct 
MVA/K1L contains the wild-type K1L ORF and its natural promoter stably inserted into 
the MVA genome [24].  Virus ΔK1L was created by replacing the K1L ORF of WR with 
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the Escherichia coli gpt gene via homologous recombination [24].  WR and ΔK1L 
viruses were amplified in BSC-1 cells, while MVA-based viruses were amplified in 
chicken embryo fibroblasts (Charles Rivers Laboratories). 
Five recombinant viruses containing stably re-introduced wild-type or mutated 
K1L ORFs were used in these studies: vC7L-K1L+, S2N, S2C, S2C #2 and S2C#3, and 
their construction was described previously [11].  The parent virus for each of these 
viruses was vC7L-K1L-, in which the C7L and K1L ORFs were deleted from the WR 
genome.  For the creation of vC7L-K1L+, a cassette containing the V5 epitope-tagged 
K1L ORF and its natural promoter and an adjacent green fluorescing protein (GFP) gene 
under control of the P11 late promoter were stably re-inserted into vC7L-K1L- [11].  
Thus, cells infected with these viruses also express GFP.  Virus S2N was created 
similarly, except that ankyrin repeat 2 of the K1L ORF was mutated at residues 63, 67 
and 70-75, and then inserted into vC7L-K1L-[11].  S2C is a virus that codes for a mutated 
K1 product, in which the ankyrin repeat 2 C-terminal residues 78,79, 82, 83, 85 and 87-
90 are mutated [11].  Viruses S2C#2 and S2C#3 express mutant K1L product in which 
residues 81,82 and 84 or 86-88 are mutated, respectively [11].  These recombinant 
viruses were amplified in Vero cells. 
 
Immunoblot analysis.   
Cytoplasmic extracts were collected according to a modified protocol described 
previously [24]. Confluent monolayers of cells in 6-well tissue culture dishes were 
infected with the indicated viruses at an MOI of 10 with an absorption incubation for 60 
min in DMEM containing 2.5% FCS.  At the times indicated post-infection, cellular 
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monolayers were dislodged from their wells by scraping and the cells were collected by 
centrifugation (30 sec at 14,000 × g).  As a positive control for eIF2α phosphorylation, a 
separate set of mock-infected RK13 cells was incubated in medium containing 10 µM 
thapsigargin (Sigma-Aldrich) for 4 h before cells were collected by scraping.  Cellular 
pellets were resuspended and lysed in cytoplasmic extraction buffer (CE) that contained 
the HALT protease inhibitor cocktail (Pierce) for 5 minutes at 4°C.  After a brief 
centrifugation (30 sec at 14,000 × g), the resultant supernatants were collected and 
transferred to new microfuge tubes.  The protein concentration of each sample was 
determined using the bicinchoninic acid (BCA) assay (Pierce).  An equal amount of 
protein (20 μg) from each sample was mixed with 5× non-reducing lane marker (Thermo 
Scientific) for a final 1× concentration that contained 5% 2-mercaptoethanol (Fisher 
Scientific), boiled for 5 min, and briefly incubated on ice.  Next, the proteins were 
electrophoretically separated by using SDS-12%PAGE.  Following electrophoresis, 
proteins were transferred to a polyvinyl difluoride (PVDF) membrane (Millipore) and the 
membranes were incubated for 1 h in TBS containing 0.05% Tween-20 (TTBS) and 5% 
non-fat milk.  Next, membranes were incubated at 4°C overnight in primary antiserum in 
TTBS containing 5% non-fat milk.  The following primary antibodies were used: mouse 
monoclonal anti-phospho-eIF2α S51 (1:500; Epitomics), mouse monoclonal anti-eIF2α 
(1:1,000; Santa Cruz), mouse anti-phospho PKR T446 (1:1,000; Epitomics), mouse 
monoclonal anti-PKR N-terminus (1:1,000; Epitomics), mouse monoclonal anti-E3L 
antibody (1:1,000; a gift from Dr. Stuart Isaacs, School of Medicine, University of 
Pennsylvania)[27], mouse monoclonal anti-L1R antibody (1:1,000; a gift from Dr. Jay 
Hooper, Virology Division, United States Army Medical Research Institute for Infectious 
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Disease, Fort Detrick, Maryland) or rabbit polyclonal anti-K1L antiserum (1:500).  
Immunoblots were washed in TTBS and incubated in a TTBS solution containing either 
goat-anti-rabbit immunoglobulin G (IgG; 1:10,000) or goat-anti-mouse IgG conjugated 
with horseradish peroxidase (1:10,000; Fischer Scientific).  Immunoblots were developed 
using SuperSignal West chemilluminescence reagents per the manufacturers directions 
(Pierce).   
 
Detection of GFP-expressing viruses and plaque phenotypes.   
Confluent monolayers of HeLa or PKRkd cells in 6-well issue culture plates were 
infected at an MOI of 0.01 PFU/cell of either WR, vC7L-K1L+, S2N, S2C, S2C#2, or 
S2C#3.  At 48 hours post-infection, GFP-expressing plaques were detected and 
visualized and photographed by using an inverted fluorescence microscope (Olympus, 4× 
objective). Following the microscopic examination of infected cellular monolayers, 
supernatants were removed from monolayers, and 2 ml of a 20% ethanol solution 
containing 1% crystal violet was added to each well.  After a 5 min incubation, the 
solution was removed and plates were air-dried to visualize virus plaques. 
 
[35S]-Methionine labeling of virus infected cells.  
Confluent monolayers of HeLa or PKRkd cells in 6-well tissue culture plates were 
mock-infected or infected at an MOI of 10 PFU/cell with either vC7L-K1L+ or S2C#2.  
Thirty minutes before harvesting, each cell was washed twice with DMEM lacking 
methionine and cysteine (DMEMMet-Cys-; Hyclone), and subsequently replenished with 
0.5 ml of DMEMMet-Cys- containing 75 µCi EXPRE35S35S protein labeling mix (Perkin 
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Elmer). Cells were harvested at 0.5, 2, 4 and 24 hours post-infection by scraping, and 
collected by centrifugation.  Pelleted cells were lysed in CE buffer as described above.  
Equal volumes of clarified lysates were analyzed by using 10% SDS-PAGE.  Gels were 
dried in a gel drier, exposed to phosphoimager screens, and images were developed by 
using phosphoimaging. 
 
3) Results 
 
The K1 product is required and sufficient to inhibit virus-induced eIF2α 
phosphorylation in RK13 cells.  
 
The vaccinia K1 product is required for a productive vaccinia infection of RK13 
cells [15].  The cowpox virus CP77 protein can compensate for K1 during infection of 
RK13 cells, restoring replication proficiency of vaccinia viruses lacking the K1L ORF 
[18].  Since the CP77 product was reported to possess eIF2α inhibitory function [9], we 
queried if the K1 product affected this event.  To this end, RK13 cells were infected with 
viruses containing or lacking the K1L ORF, and cytoplasmic extracts were examined by 
using immunoblotting, incubating blots with antibodies that recognize eIF2α 
phosphorylated at serine 51 (p-eIF2α). 
As shown in Figure 2.1A, infection of cells with the wild-type Western Reserve 
[8] strain of vaccinia virus prevented eIF2α phosphorylation, as observed by low levels 
of p-eIF2α.  In contrast, p-eIF2α levels were increased in cells infected with ∆K1L, a 
mutant WR virus that lacks the K1L ORF [24], inferring that the presence of K1 proteins 
prevented virus-induced eIF2α phosphorylation.  The highest amount of p-eIF2α present 
during infection, as detected by an increase in band intensity, occurred at 3 h post-
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inoculation (pi), and this form was detectable at all times tested.  Treatment of mock-
infected cells with thapsigargin, a known inducer of p-eIF2α [16], resulted in the 
presence of a band with the same mobility.  The relative quantities of unmodified eIF2α 
for each sample remained fairly constant, as measured by immunoblotting with 
antibodies recognizing only the native (unphosphorylated) form of eIF2α.  Thus, the 
differences in p-eIF2α levels were not due to protein degradation.  Similar results were 
observed if rabbit kidney epithelial LLC-RK1 cells or rabbit lung fibroblast R9AB cells 
were utilized instead (data not shown), indicating that the K1 protein’s inhibitory effect 
occurred in several cell lines.  However, p-eIF2α was not detected in ∆K1L-infected 
human kidney fibroblast 293 cells or mouse fibroblast NIH3T3 cells, inferring that the 
effect of the K1 protein was cell-type specific. 
Modified vaccinia Ankara (MVA) is an attenuated vaccinia virus strain lacking a 
wild-type K1L ORF [1].  Thus, it was not surprising to observe eIF2α phosphorylation in 
lysates from MVA-infected RK13 cells, with p-eIF2α detected as early as 1 hour post-
infection (h pi) (Figure 2.1B).  eIF2α phosphorylation was long-lasting since this 
modified form of eIF2α was still detected in cells collected at 6 h pi.  The re-insertion of 
a wild-type K1L ORF into MVA (MVA/K1L) resulted in a virus that no longer triggered 
eIF2α phosphorylation, suggesting that the K1L ORF was sufficient to prevent p-eIF2α 
in RK13 cells.  As with Figure 2.1A, unmodified eIF2α levels in immunoblots were 
similar for all samples, inferring that the differences in p-eIF2α levels were not due to 
inadequate levels of proteins in each sample.  Similar results were also observed during 
infection of either LLC-RK1 or R9AB cells (data not shown). 
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Mutations in the ankyrin repeat 2 affects the ability of the K1 product to inhibit 
eIF2α phosphorylation in RK13 cells. 
 
The K1 protein possesses 6 ankyrin [23] repeats, motifs important for protein-
protein interactions [11, 21].  Substitution mutations of residues in the K1 ANK repeats 
1, 2, 3 or 5 result in a non-productive infection of RK13 cells [11], inferring that these 
residues are critical for K1 molecular function.  To assess if these same residues were 
important for eIF2α inhibitory function of K1, p-eIF2α was measured in lysates from 
cells infected with viruses expressing mutant K1 proteins.  Studies were focused on 
mutations in the K1 ANK2 region, a region in which discrete substitution mutations had 
identified residues in the ANK2 region necessary for virus replication [11]. 
Five recombinant viruses were utilized for this study.  For this set of viruses, 
wild-type or mutant K1L ORFs were stably introduced into a WR-based virus lacking 
both the C7L and K1L ORFs [11]. Virus vC7L-K1L+ contains a re-inserted wild-type 
K1L ORF possessing a V5 epitope tag [11].  The S2N and S2C viruses, in contrast, 
express V5 epitope-tagged K1 proteins with mutations in the N or C terminus of ANK2, 
respectively [11].  S2C#2 and S2C#3 possessed mutations in the C-terminal region of 
ANK2, with S2C#2 containing mutations at residues 81, 82 and 84, and S2C#3 
containing mutations at residues 86-88 [11].   
As would be expected, vC7L-K1L- infection rendered the same phenotype as 
∆K1L infection of RK13 cells: eIF2α was phosphorylated under these conditions (data 
not shown).  In RK13 cells, the C7L ORF was not required to inhibit eIF2α 
phosphorylation:  p-eIF2α levels were comparable in cells infected with a virus lacking 
only the C7L ORF (vC7L-K1L+) versus those infected with WR (Figure 2.2A and 2.2B), 
and were lower than those detected in ∆K1L-infected cells.  Expression of a mutant S2C 
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K1 protein, in which nine conserved and non-conserved amino acid substitution 
mutations were introduced into the C-terminal half of the K1L ANK2 region [11], 
resulted in increased peIF2α levels, indicating that these residues were important for K1 
function.  P-eIF2α remained detectable if cells were instead infected with the S2C#2 
virus, a virus in which only ANK2 residues 81, 82 and 84 were substituted [11], 
indicating the importance of these three residues in preventing eIF2α phosphorylation.  In 
contrast, p-eIF2α levels were greatly decreased in cells infected with S2C#3, in which 
residues 86-88 are mutated [11], indicating that these C-terminal residues were not 
critical for the K1 inhibitory function.  Interestingly, amino acid residues in the ANK2 N-
terminus were also important for inhibitory function since p-eIF2α was detected in S2N-
infected cells (Figure 2.2B).  When comparing these results to residues important for the 
K1 host-range function [11], the same mutations that altered the K1 host-range function 
also altered the K1 function of preventing eIF2α phosphorylation in RK13 cells.  
Unmodified eIF2α was present in similar amounts for each immunoblotted sample, 
indicating that the variation observed in p-eIF2α levels was not due to uneven protein 
loading of gels.   
 
Virus-induced eIF2α phosphorylation occurs despite vaccinia E3 protein expression.  
The K1L ORF is required for a productive vaccinia infection of RK13 cells [15].  
If the K1L ORF is absent, there is a reduction in viral and cellular protein synthesis, with 
little nascent protein synthesis detected at 2 h pi [18].  Under this condition there may be 
little to no expression of the vaccinia E3 product, a protein that binds to double-stranded 
RNA to prevent PKR activation and subsequent eIF2α phosphorylation [4].  Thus, one 
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concern was that eIF2α phosphorylation in ∆K1L- or S2C#2-infected RK13 cells was 
due to the absence of E3 proteins, and not to an inherent inhibitory biochemical property 
of the K1 product.   
To investigate this possibility, E3 protein levels were detected in virus-infected 
cells by using immunoblotting, probing membranes with antiserum recognizing the E3 
protein [27].  E3 proteins were synthesized and stable during RK13 infection since E3 
proteins were detected in all infected cells at all times measured pi, as was evidenced by 
the presence of a 25-kDa band (Figure 2.3).  Thus, it was unlikely that virus-mediated 
eIF2α phosphorylation was due to the absence of E3 proteins.  Other vaccinia early 
proteins (M2 and J3) were also detected in ∆K1L-infected cells (data not shown), 
suggesting that ∆K1L infection allows for the synthesis of other early gene products.  In 
comparison to WR- or vC7L-K1L+-infected cells, it should be noted that E3 proteins 
were reduced in ∆K1L- and S2C#2-infected RK13 cells (Figure 2.3).  Detection of 
similar levels of actin for each sample indicated that the differences observed for E3 
protein expression was not due to uneven loading of samples.  
Wild-type and mutant K1 proteins were expressed in similar levels in virus-
infected cells (Figure 2.3), suggesting that the substitution mutations did not cause gross 
misfolding of K1 proteins.  Whether these mutations resulted in more subtle changes in 
protein conformation cannot be excluded.  However, it should be noted that the residues 
altered in the S2C#2 construct were predicted to be residues located on the surface of the 
K1 protein, where the mutations were likely to have the least impact on protein folding 
[11].  The K1 products from vC7L-K1L+-infected cells possessed a higher mobility than 
those from WR-infected cells, reflecting the presence of a V5 epitope tag [11].  Mutant 
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S2C#2 proteins, which did not prevent eIF2α phosphorylation (Figure 2.2), were also 
detected at all times post-inoculation.  Similar to a previous report, this V5 epitope-
tagged mutant protein possessed a higher gel mobility than its wild-type counterpart [11]. 
As shown in Figure 2.3, E3 protein levels were decreased in cells infected with 
either ∆K1L or S2C#2, viruses that mediated eIF2α phosphorylation.  To ensure that 
reduced E3 protein expression was independent of eIF2α phosphorylation, studies were 
repeated in RK13 cells stably expressing the vaccinia E3L product (RK13-E3L).  As an 
indication that the E3 protein in RK13-E3L cells is functional, poly I:C-induced p-eIF2α 
levels were decreased as compared to those observed for similarly treated RK13 cells 
(data not shown).  In contrast to RK13 cells, E3 protein expression in ∆K1L- or S2C#2-
infected cells remained similar to that observed in infected cells expressing wild-type K1 
proteins in RK13-E3L cells (Figure 2.4).  Despite the equal E3 protein levels, p-eIF2α 
remained higher in ∆K1L- or S2C#2-infected RK13-E3L cells as compared to WR- or 
vC7L-K1L+-infected RK13-E3L cells, at all times pi measured, suggesting that E3 
protein levels did not dictate eIF2α phosphorylation.  As a control, regular RK13 cells 
were infected and processed in parallel with RK13-E3L cells (Figure 2.4).  As would be 
expected, p-eIF2α levels were increased in regular cells infected with either ∆K1L or 
S2C#2 compared to WR or vC7L-K1L+, similar to results shown in Figure 2.2. 
 
The K1 product inhibits virus-induced eIF2α phosphorylation in the human HeLa 
cell line. 
 
Continued studies of the K1 molecular function in RK13 cells were difficult due 
to the commercial paucity of antibodies that react with rabbit proteins.  Thus, similar 
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experiments were performed in human cells, in which more reagents are available.  The 
HeLa cell line was chosen for further study since the K1L ORF acts as a host-range gene 
in this cell line [15].  In contrast to RK13 cells, in which removal of the K1L ORF is 
sufficient to inhibit vaccinia replication, in HeLa cells, the K1L host-range effect is only 
observed in the absence of the C7L ORF [15].  The C7 product was also reported to 
inhibit eIF2α phosphorylation [14].  Thus, studies performed in these cells required 
viruses that lacked the C7L ORF [11].  Recombinant viruses expressing wild-type or 
mutant K1 proteins used for the above studies in RK13 and RK13-E3L cells indeed 
lacked the C7L ORF [11], enabling us to evaluate the role of the K1 protein in the 
absence of C7L gene expression in HeLa cells.  Studies comparing p-eIF2α in MVA 
versus MVA/K1L-infected cells were not performed using HeLa cells.  MVA infection of 
HeLa cells does not result in eIF2α phosphorylation [14].  Thus, MVA/K1L infection of 
HeLa cells would result in the same phenotype as MVA-infected cells. 
eIF2α phosphorylation was examined in virus-infected HeLa cells, and p-eIF2α 
was detected by using immunoblotting.  Results are shown in Figure 2.5.  In HeLa cells, 
unmodified eIF2α was present in mock-infected cells or in cells infected with a virus 
containing the wild-type K1L ORF (vC7L-K1L+).  The K1 ANK2 C-terminus was 
responsible for the inhibitory phenotype, since p-eIF2α was detected in HeLa cells 
infected with S2C, but not S2N.  Of note, infection of HeLa cells with the S2N virus 
rendered a different eIF2α phenotype than observed with RK13 cells: the mutant S2N 
protein prevented eIF2α phosphorylation in HeLa cells at 4 h pi (Figure 2.5) or at 6 h pi 
(data not shown).  In contrast, infection of RK13 cells with S2N no longer inhibited this 
action (Figure 2.2B).  Upon further analysis of ANK2 C-terminal region, ANK2 residues 
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81, 82 and 84 were important for inhibiting eIF2α phosphorylation since S2C#2 infection 
resulted in eIF2α modifications.  As with RK13 cells, the presence of p-eIF2α during 
infection correlated with a replication defective phenotype in HeLa cells [11].  
 
Inhibition of virus-induced eIF2α activation in HeLa cells is independent of E3 
protein expression. 
 
As with RK13 cells, it was important to eliminate the possibility that eIF2α 
phosphorylation was due to a lack of E3 protein synthesis in virus-infected HeLa cells.  
Thus, E3 proteins were detected in vaccinia virus-infected HeLa cells by using 
immunoblotting, similar to experiments shown in Figure 3.  E3 proteins were detected at 
early and late times post-infection, in all virus-infected cells, suggesting that eIF2α 
phosphorylation was not due to an absence of E3 proteins (Figure 2.6).  It was noted that 
E3 protein levels, while detectable, were lowest in cells infected with S2C#2, a virus that 
did not prevent eIF2α activation in HeLa cells (Figure 2.6).  Although it cannot be ruled 
out that the decreased E3 protein levels are responsible for eIF2α phosphorylation, data 
from Figures 2.3 and 2.4 would indicate that E3 protein levels are independent of the K1 
phenotype in HeLa cells.  Mutant and wild-type K1 proteins were detected in fairly 
similar amounts in infected cells (Figure 2.6).  Thus, the reduction in E3 protein levels 
did not appear to be due to K1 protein synthesis or stability.  As before, the V5 epitope-
tagged K1 products expressed in vC7L-K1L+- or S2C#2-infected cells possessed a higher 
mobility than wild-type K1 products expressed during WR infection (Figure 2.6). 
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The PKR protein is responsible for eIF2α phosphorylation in vaccinia virus-infected 
cells. 
 
Several cellular proteins are known to phosphorylate eIF2α, including PKR, 
PERK, GCN2 and HRI [17].  Commonly, PKR is responsible for eIF2α phosphorylation 
during virus infection, thus we assessed if the PKR protein was responsible for eIF2α 
phosphorylation in vaccinia virus-infected cells.  To this end, we assessed virus-induced 
eIF2α phosphorylation in HeLa cells in which >95% of PKR protein expression is stably 
silenced [31].  This cell line is referred to as PKRkd.  Similar to previous studies [31], 
PKR proteins were either undetectable or greatly reduced in lysates from PKRkd cells 
versus normal HeLa cells, regardless of whether cells were mock-infected or infected 
(Figure 2.7).  The decrease in PKR proteins did not grossly affect eIF2α protein stability 
since eIF2α was present in similar amounts in PKRkd versus HeLa cells.  P-eIF2α levels 
were greatly decreased when PKRkd cells were infected with viruses that normally 
allowed for eIF2α phosphorylation in parental HeLa cells, such as S2C#2 and S2C, 
inferring that PKR proteins were required for virus-mediated eIF2α phosphorylation.  
Equally important, eIF2α remained unmodified in vC7L-K1L+-, S2C#3-, and S2N-
infected PKRkd cells, as would be expected. 
 
The K1 function of preventing virus-mediated PKR activation is not related to its 
host range function in HeLa cells. 
 
It was noticed that only K1-expressing viruses that inhibited eIF2α 
phosphorylation allowed for a productive infection in RK13 and HeLa cells [11].  These 
data suggested that a block in eIF2α phosphorylation, which would allow for translation 
initiation, is the K1 mechanism for allowing a productive infection.  If this is correct, then 
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PKR-deficient cells should lack a mechanism to phosphorylate eIF2α, and should be 
permissive for virus replication, regardless of the absence of a functional K1 product.  To 
test this, we detected viral protein synthesis in HeLa cells lacking PKR proteins (PKRkd), 
comparing the phenotypes to virus growth in normal HeLa cells possessing functional 
PKR proteins (Fig 2.8A).  The infection of HeLa cells with S2C#2, a virus unable to 
replicate in HeLa cells [11], resulted in the dramatic decrease of viral protein synthesis at 
4 and 24 h pi.  This effect was not observed if HeLa cells were instead infected with a 
virus expressing a wild-type K1 protein.  In PKRkd-infected cells, modest levels of 
protein synthesis were still observed at 4 and 24 h pi, suggesting that the elimination of 
PKR indeed allowed for some viral protein synthesis.  When detecting an individual early 
(E3) or late (L1) protein under these same conditions, E3 proteins were still detected (Fig. 
2.8B).  In contrast, L1 proteins were no longer detected in S2C#2-infected PKRkd cells, 
suggesting that the elimination of PKR, while allowing for partial restoration of viral 
protein synthesis, was not sufficient for allowing robust expression of viral late proteins.  
Due to the lack of late protein synthesis, no visible plaques were observed in PKRkd 
monolayers infected with S2C#2 (or S2C) (Fig 2.8C).  The recombinant viruses also 
express a GFP gene under the control of the p11 late promoter [11], allowing for the 
visualization of individual plaques by fluorescent microscopy.  In agreement with data 
from Figure 2.8C, no GFP-expressing plaques were observed for PKRkd cells infected 
with S2C#2 (Fig 2.8D).  The WR, vC7L-K1L+, S2C#3 and S2N viruses maintained their 
abilities to replicate in PKRkd cells, as evidenced by the presence of microscopic (Fig 8C) 
and visual  (Fig 8D) plaques.  GFP-expressing plaques formed during vC7L-K1L+, 
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S2C#3 or S2N infection were noticeably smaller in PKRkd versus normal HeLa 
monolayers. 
 
The K1 product prevents PKR phosphorylation, an event correlative with its ability 
to inhibit eIF2α phosphorylation. 
 
For PKR to become activated, it forms a dimer, resulting in its auto-
phosphorylation [6].  We observed that the K1 protein prevented eIF2α phosphorylation.  
There were two likely mechanisms responsible for this phenotype.  First, the K1 protein 
may interact with eIF2α, thereby preventing activated PKR from phosphorylating eIF2α.  
Alternatively, the K1 protein may prevent PKR auto-phosphorylation as its mechanism 
for inhibition.  To test the later possibility, we assessed if the K1 product prevented PKR 
activation.  HeLa cells were infected with viruses expressing wild-type or mutant K1 
proteins, and PKR activation was assessed by detecting the phosphorylated (activated) 
form of PKR by using immunoblotting.  Wild-type K1L proteins prevented PKR 
activation, as judged by the absence of p-PKR (Figure 2.9).  This function was also 
detected in cells infected with mutant viruses that inhibited eIF2α phosphorylation 
(S2C#3 and S2N), suggesting that the K1 protein affected the ability of PKR to auto-
phosphorylate.  Conversely, PKR was activated when cells were infected with either 
S2C#2 or S2C, viruses that no longer inhibited eIF2α phosphorylation.  Anti-PKR 
antiserum that simultaneously recognizes the modified and unmodified PKRs was used to 
detect similar PKR levels in each well.  Interestingly, although activated PKR was 
present in S2C#2- and S2C-infected cells, a population of inactive PKR proteins was also 
detected.  
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4) Discussion 
 Here, we report a novel function for the vaccinia K1 protein; it inhibits PKR 
activation.  Since active PKR attenuates protein synthesis, one attractive hypothesis was 
that the K1 protein, in preventing PKR activation, would allow for virus replication in 
RK13 and HeLa cells.  This model was bolstered by the observation that viruses that 
allowed PKR activation or eIF2α phosphorylation were not replication competent in 
HeLa or RK13 cells [11], respectively.  While PKR-deficient HeLa cells indeed allowed 
for a partial restoration of viral protein synthesis, these cells remained unable to support 
the synthesis of the late L1 protein or the replication of S2C#2.  Thus, K1’s PKR 
inhibitory phenotype only partially contributes to permissivity in HeLa cells.  One 
conclusion from this study is that there are PKR-independent mechanisms for controlling 
viral protein synthesis during infection.  For example, for translation to occur, capped 
mRNA must be complexed with eIF4F, a complex that is formed only upon the 
inactivation of eIF4E binding proteins.  Vaccinia virus infection inactivates the 4E-BP1 
binding protein to promote eIF4F complex formation.  Whether this event is critical to 
the host-range phenotype is unknown [26]. 
 The E3 and K3 proteins are expressed early in infection, and each inhibit PKR 
activation [19, 20, 22, 25].  ∆K1L infection of RK13 cells results in a dramatic decrease 
in early gene translation [18], which would presumably include E3 and K3 protein 
synthesis.  Thus, an initial concern was that the ∆K1L effect in these rabbit cells was 
indirect, due to a lack of E3 and K3 proteins.  However, we found that E3 proteins were 
expressed in RK13 cells, regardless of the absence of the K1L ORF.  Further examination 
revealed that other early proteins, such as the M2 and J3 products, were also detected in 
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∆K1L-infected RK13 cells (data not shown), suggesting that the K3 protein would also 
be synthesized during infection as well.  Since early protein synthesis, as measured by the 
[35S]-methionine metabolic labeling of nascent proteins during virus infection, was 
detected for at least one hour after ∆K1L infection of RK13 cells [18], our results were 
not surprising.   Most important, these data indicate that the PKR activation phenotype in 
∆K1L-infected RK13 cells is not indirect; i.e., PKR activation in ∆K1L-infected cells is 
not simply due to a lack of E3, or other known or undiscovered, PKR inhibitory proteins.  
For HeLa cells, infection with viruses lacking both the K1L and C7L ORFs results in a 
block in intermediate gene translation [7].  Thus, E3 proteins are expected to be 
synthesized, an event we detect in our system. 
We identified that the ANK2 repeat of K1 is required for PKR inhibitory function, 
but cannot rule out that other K1 ANK repeats may also possess inhibitory function.  
Given that other ANK repeats of K1 are important for its host-range function [11], one 
prediction is that mutations in other ANK repeats would be expected to affect K1’s PKR 
inhibitory function.  We purposefully limited our studies to the ANK2 region since the 
smallest number of amino acid substitutions was made in this repeat [11].  Further, two of 
these constructs (S2C#2 and S2C#3) yielded different host range phenotypes, 
characteristics that would enable us to easily assess if PKR activity and host range 
phenotype were related.  
ANK repeats are 33 residues in length, and the motif is defined as a β-hairpin-
helix-loop-helix structure [21].  These motifs are found in proteins in nearly all phyla, 
and have myriad functions [21].  Diversity in binding partners for ANK-containing 
proteins is attained by variation in the surface residues of ANK repeats, and by the 
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number of ANK repeats stacked together to form a stable structure [21].  Substitution 
mutations were originally made in the ANK2 region that would only affect surface 
residues, affecting potential binding site for K1 interacting partners, but allowing for the 
ANK repeat to keep its structure, since structure is likely important for its ability to 
interact with its target protein [11].  The mutated residues in S2C#2 lie in the outer helix, 
a potential surface for protein-protein interactions, while the mutations in S2C#3 lie 
downstream of the outer helix [11].  Thus, the finding that the S2C#2 virus allowed for 
PKR activation likely reflects a loss of binding to a target protein.  A previous study 
identified a rabbit homolog of the human cellular ACAP2 protein that interacts with K1 
protein in vaccinia-infected RK13 cells [3].  Whether K1-ACAP2 interactions are critical 
for its ability to inhibit PKR activity is an area of future research.  It was noticed that the 
ANK2 regions responsible for PKR inhibition were different for RK13 versus HeLa cells.  
For RK13 cells, residues in both the N and C terminal portion of ANK2 were necessary 
for inhibitory function, while residues only in the C terminal portion of ANK2 were 
important for HeLa cells.  These differences may indicate that the K1 protein interacts 
with a different subset of rabbit versus human proteins. 
While activated PKR is best known for its anti-viral effect of inhibiting protein 
synthesis, it possesses other biological properties that neutralize virus infections [6].  For 
example, PKR also induces apoptosis, a rapid form of cell death that eliminates virus-
infected cells [9].  The ability of the K1 protein to prevent PKR-induced apoptosis is 
unknown.  PKR also activates the NF-κB transcription factor [10, 30].  Since this cellular 
transcription factor induced the expression of anti-viral immune molecules, this property 
of PKR could also inhibit virus replication.  To date, there are multiple vaccinia proteins 
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that inhibit PKR activity, including K1, C7, E3 and K3 [6].  For this model system, in 
which HeLa cells are used, it does not appear that the E3L or the K3L ORF, both of 
which are present and presumably expressed during virus infection, are involved in virus-
mediated PKR activation.  These data would argue that molecules in addition to dsRNA, 
including PACT and Mda7, activate PKR during poxvirus infection.  Furthermore, the 
presence of myriad vaccinia proteins likely reflect the fact that different insults activate 
PKR, rendering anti-viral biological effects.  
The CP77, K1 and C7 proteins can functionally complement each other to allow 
for a productive vaccinia infection in HeLa cells [15].  These three proteins also prevent 
PKR activation [7, 12].  The K1 and CP77 proteins both possess ankyrin repeats.  The 
CP77 protein also has an F-box motif [5], a motif lacking in the K1 protein.  In contrast, 
no obvious F-box or ankyrin motifs are present in C7 proteins.  One prediction, then, is 
that the CP77 and K1 proteins will utilize similar molecular mechanisms to alter PKR 
activation, while the C7 product will likely utilize a mechanism distinct from CP77 or 
K1.  As shown here, the K1 protein prevents PKR activation, as measured by an 
inhibition of PKR phosphorylation.  The K1 protein lacks an obvious dsRNA binding 
motif, making it unlikely that K1 functions like the E3 protein, binding to dsRNA as its 
mechanism to inhibit PKR activation.  A simple explanation for K1’s molecular 
mechanism is that the K1 protein binds to PKR, preventing its dimerization and 
subsequent auto-phosphorylation.  Ankyrin repeats, like the ones present in K1, are 
important for mediating protein-protein interactions [2], making it reasonable to suggest 
that the K1 protein could form a stable complex with PKR.  A second possibility is that 
the K1 protein indirectly inhibits PKR activation by binding to cellular PKR activating 
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proteins, such as PACT and Mda7 [6, 32].  Thus, future directions include assessing K1 
interactions with the above proteins and assessing if K1 binding function correlates with 
PKR inhibition.   
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5) Figures 
 
 
Figure 2.1 eIF2α phosphorylation in virus-infected RK13 cells.  RK13 cellular 
monolayers were mock-infected (UN) or infected at an MOI of 10 with either (A) WR or 
∆K1L, or (B) MVA or MVA/K1L (MOI = 10), and infections proceeded for the indicated 
times.  For both experiments, a separate set of mock-infected RK13 cells were incubated 
in medium containing thapsigargin (thaps) for 4 h as a positive control for eIF2α 
phosphorylation.  Regardless of treatment, cells were collected and lysed in CE buffer.  
Equal amounts of prepared cytoplasmic extracts (20 µg) were electrophoretically 
separated by SDS-12% PAGE and transferred to PVDF membranes.  Membranes were 
probed with antiserum recognizing either the phosphorylated (p-eIF2α) or unmodified 
forms of eIF2α.  Molecular weight markers (MW) are indicated. 
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Figure 2.2 The effect of K1L mutations on eIF2α phosphorylation. (A) RK13 cellular 
monolayers were mock-infected (UN) or infected at an MOI of 10 with (A) ∆K1L, WR, 
S2C, S2C#2, or vC7L-K1L+ or (B) ∆K1L, WR, vC7L-K1L+, S2C#2, S2N or S2C#3.  
Unless indicated otherwise, infections proceeded for 4 h pi.  Cytoplasmically extracted 
proteins were separated by using SDS-12% PAGE and then transferred to PVDF 
membranes.  Immunoblots were used to detect phosphorylated (top panel) or unmodified 
(bottom panel) forms of eIF2α. Molecular weight markers (MW) are indicated. 
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Figure 2.3 E3 and K1 product levels in virus-infected RK13 cells.  Cellular 
monolayers were mock-infected (UN) or infected with WR, ∆K1L, S2C#2, or vC7L-
K1L+ (MOI = 10).  At 4, 8 or 12 h pi, cells were harvested and immunoblotted lysates 
were probed with antiserum recognizing the vaccinia E3 product.  The same membrane 
was re-probed for unmodified or V5 epitope tagged K1 products by incubating the 
immunoblot with anti-K1 antiserum.  The mobilities of wild-type or mutant K1 proteins 
are indicated. Equal protein loading was confirmed by probing the same membrane with 
anti-actin antiserum.  Molecular weight markers (MW) are indicated. 
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Figure 2.4 eIF2α phosphorylation in RK13 cells stably expressing the vaccinia E3 
product.  RK13 or RK13-E3L cellular monolayers were infected with either WR, ∆K1L, 
vC7L-K1L+ or S2C#2 at an MOI of 10 PFU/cell.  At 4 h post-infection, cells were 
harvested, and immunoblotted lysates were incubated with antiserum specific for the 
active (phosphorylated) form of eIF2α, and then re-probed with antiserum raised against 
the unmodified form of eIF2α and the vaccinia E3 protein. 
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Figure 2.5 eIF2α phosphorylation in virus-infected HeLa cells.  HeLa cellular 
monolayers were mock-infected (UN) or infected with vC7L-K1L+, S2C#2, S2C#3, S2C 
or S2N at an MOI = 10.  Infections proceeded for 4 h pi.  Immunoblots containing 
cytoplasmically extracted proteins were probed with antiserum recognizing either the 
phosphorylated (top panel) or unmodified (bottom panel) form of eIF2α.  Molecular 
weight markers (MW) are indicated. 
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Figure 2.6 E3 protein levels in virus-infected HeLa cells.  Cellular monolayers were 
mock-infected (UN) or infected with ∆K1L, WR, S2C#2, or vC7L-K1L+ (MOI = 10).  At 
4, 8 or 12 h post-infection, cells were processed, and immunoblots were probed with 
antiserum recognizing the vaccinia E3 product.  The same membrane was re-probed for 
K1 products by incubating the immunoblot with anti-K1 antiserum.  Molecular weight 
markers (MW) are indicated. 
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Figure 2.7 The effect of decreased PKR protein levels on eIF2α phosphorylation in 
virus-infected HeLa cells.  HeLa cells expressing PKR (HeLa) or lacking PKR (kd) 
were either mock-infected (UN) or infected with either vC7L-K1L+, S2C#2, S2C#3, S2C 
or S2N (MOI = 10).  At 4 h pi, cells were harvested and subjected to immunoblotting 
with antiserum recognizing either the phosphorylated or unmodified forms of eIF2α.  The 
same immunoblot was probed with anti-serum specific for the PKR protein.  Molecular 
weight markers (MW) are indicated. 
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Figure 2.8 Virus plaque formation in HeLa cells expressing or lacking PKR 
proteins.  HeLa cellular monolayers either expressing PKR proteins (HeLa) or deficient 
for PKR proteins (PKRkd) were infected with the indicated viruses at (A and B) an MOI 
of 10 or (C and D) an MOI of 0.01 PFU/cell.  (A) At 30 min before harvesting, infected 
cellular monolayers were incubated in medium containing 35[S]-methionine.  Cells were 
collected and lysed, and an equal volume of each lysates was separated by SDS-
10%PAGE.  Dried gels were imaged by using phosphorimaging.  (B) Infected HeLa or  
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Figure 2.8 (continued) 
PKRkd cells were collected at the times indicated, and lysed in CE buffer.  Lysates were 
analyzed by SDS-12%PAGE, and proteins were transferred to PVDF membranes.  
Immunoblots were probed with antiserum recognizing either the L1 or E3 vaccinia 
proteins.  Molecular weight markers (MW) are indicated.  (C) At 48 h post-infection, 
media was replaced with a 20% ethanol solution that contained 1% crystal violet.  After a 
10 min incubation, supernatants were removed and plates were air-dried.  (D) GPF-
expressing infected cells were detected by using fluorescence microscopy at 48 h pi.   
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Figure 2.9 The effect of virus infection on PKR activation.  HeLa cell monolayers 
were mock-infected (UN) or infected with either vC7L-K1L+, S2C#2, S2C#3, S2C or 
S2N at an MOI of 10.  At 4 h post-infection, cells were harvested, prepared for 
immunoblotting and probed with antiserum recognizing either the phosphorylated form 
of PKR (p-PKR) or the unmodified form. Molecular weight markers (MW) are indicated. 
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Chapter 3: Viral dsRNAs from vaccinia virus early or intermediate gene transcripts 
possess PKR activating function, resulting in NF-κB activation, when the K1 protein 
is absent or mutated 
 
1) Introduction 
Mammalian cells express proteins to detect and defend against virus infection.  Such 
molecules are pattern recognition receptors (PRRs) and identify viral nucleic acids or 
proteins.  One such molecule is Protein kinase RNA-activated (PKR), which recognizes 
and responds to viral double-stranded RNA (dsRNA).  dsRNA-PKR interactions induce 
PKR dimerization and activate PKR.  Active PKR functions as a kinase to stimulate 
several anti-viral effects [16].  For example, PKR phosphorylates eIF2α, an event that 
halts viral protein synthesis to abort an infection.  Additionally, PKR activates the NF-κB 
transcription factor in virus-infected cells to induce a pro-inflammatory immune 
response.  PKR also stimulates apoptosis, which may lyse virus-infected cells before 
mature infections virions are formed.  Consequently, PKR is an integral part of the host 
defense against viruses [16]. 
dsRNA is often a byproduct of viral genomic replication and gene expression.  
For example, poxviruses produce large quantities of dsRNA late in infection.  dsRNA 
formation is due to two features of the transcription of intermediate and late poxvirus 
genes.  First, poxviral gene transcription can occur from either the plus or the minus 
strand of the dsDNA genome.  Second, poxvirus intermediate and late transcripts are 
heterogeneous at their 3’ ends [28].  Thus, transcripts from one DNA strand can often 
read through into regions of the genome that are transcribed from the opposite strand, 
resulting in the synthesis of significant quantities of complementary RNA that form 
dsRNAs [28].  This event is thought not to occur when poxvirus early genes are 
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expressed; early RNAs are uniform in size due to the presence of cis-acting elements that 
are expected to ensure the precise termination of early transcripts [12].   
To ensure successful replication, many viruses have mechanisms to inhibit 
dsRNA-induced PKR activation. Vaccinia virus (VV), a well-studied poxvirus, encodes 
several such proteins, and the E3 and K3 proteins are best characterized.  E3 binds to 
PKR or viral dsRNA produced during intermediate or late gene transcription [4, 8-10, 22, 
24,  34, 36].  Hence, PKR will be activated during VV infections in which the E3 protein 
is absent.  K3 protein is a pseudosubstrate (“decoy”) for PKR by virtue of its homology 
to eIF2α [5, 13].  It has been suggested K3 functions at stages prior to viral gene 
transcription.  VV variants lacking the K3L gene stimulate PKR activation in hamster and 
mouse cells, but not in human cells, suggesting that K3 functions in a host-specific 
manner [3, 22].   
Recently, we found that the VV K1 protein inhibits virus-induced PKR activation 
in both the rabbit kidney (RK13) and human cancer (HeLa) cell lines.  VVs lacking a 
wild-type K1L gene activate PKR whereas wild-type VVs do not.  PKR activation occurs 
despite the presence of the viral E3 and K3 proteins [26, 40], suggesting that the K1 
protein provides a novel inhibitory mechanism.  Strikingly, PKR is activated at times in 
infection before the transcription of intermediate or late genes occur [26, 40].  Based on 
these data, we hypothesized that VV infection produces dsRNA prior to intermediate and 
late gene replication.  As a corollary, the K1 protein provides a novel PKR inhibitory 
function to inhibit PKR activation induced by dsRNA synthesized from early gene 
transcripts. 
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To test the hypothesis, cells were infected with VV variants in which the K1 
protein either inhibited or allowed virus-induced PKR activation.  The PKR activation 
state was evaluated under conditions that blocked different stages of the poxvirus 
replication cycle.  The ability of RNAs purified from virus-infected cells to stimulate 
PKR activation independent of infection also was determined.  Additionally, reverse 
transcriptase PCR (RT-PCR) and confocal microscopy were used to detect and compare 
dsRNA levels in infected cells at early and intermediate times post-infection.  
Furthermore, since PKR stimulates NF-κB in poxvirus-infected cells [17, 26, 29], we 
queried if the ability of K1 to inhibit PKR was responsible for K1’s previously described 
NF-κB inhibitory function.  Results from these studies showed that PKR-activating viral 
dsRNAs were generated by early gene transcripts in RK13-infected cells or by 
intermediate gene transcripts in HeLa cells when the wild-type K1L gene was absent, 
identifying a previously unappreciated PKR activating mechanism possessed by 
poxviruses.  VV is widely used as a vaccine to protect against smallpox and as a vector 
for oncolytic therapy or vaccines against other pathogens.  Genetic manipulation of VV is 
often attempted to create safer, more effective vaccines and therapeutic vectors.  Deletion 
of the K1L gene is sometimes a component of this genetic manipulation.  Our study 
elucidates how a K1L deletion affects anti-viral signaling pathways and provides a 
rational basis for deletion of K1L in new VV vaccines and vectors. 
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2) Materials and Methods 
 
Cells, viruses and plasmids.  
Human cervical carcinoma (HeLa) or rabbit kidney epithelial (RK13) cell lines 
were obtained from the American Type Culture Collection.  HeLa cells in which >95% of 
PKR is stably knocked down (PKRkd) were obtained from Dr. Charles Samuel 
(Department of Molecular, Cellular and Developmental Biology, University of 
California, Santa Barbara) [43].   
The wild-type Western Reserve (WR) and the attenuated modified Ankara 
(MVA) strains of VV were used in these studies.  Virus ΔK1L is a mutant WR variant in 
which the K1L gene is deleted [35].  Five previously described recombinant viruses 
containing wild-type or mutated K1L genes were used: vC7L- K1L+, S2N, S2C, S2C #2 
and S2C#3 [27].  vC7L- K1L+ was created by stably re-inserting a V5 epitope-tagged 
K1L gene and its natural promoter into virus vC7L- K1L- [27].  Virus S2N was similarly 
created by the insertion a K1L gene whose product was mutated at residues 63, 67 and 
70-75 (in the N-terminal portion of the 2nd ankyrin repeat; ANK2) into vC7L-K1L- [27].  
Virus S2C encodes a mutated K1 product, in which ANK 2 C-terminal residues 78, 79, 
82, 83, 85 and 87-90 are mutated [27].  Viruses S2C#2 and S2C#3 express mutant K1L 
products in which residues 81, 82 and 84 or 86-88 are mutated, respectively [27].   
Plasmid pK1L was created by PCR amplification of the K1L gene in which a 
hemagglutinin (HA) epitope tag sequence was engineered onto the N-terminus of the 
gene product.  The amplicon was cloned into plasmid pCI such that the expression of the 
recombinant K1L gene was under the control of the CMV promoter.   
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Conditions for virus infections- Confluent cellular monolayers were either mock-
infected or infected with the indicated virus at 10 plaque forming units (PFU)/cell as 
described [40].  In some experiments, monolayers were incubated with cordycepin (COR; 
40 μg/ml; Sigma Aldrich), canavanine (CAN; 1 mM; Sigma Aldrich) or cytosine 
arabinoside (Ara C; 40 μg/ml; Sigma Aldrich) for 30 min prior to viral inoculation as 
well as during the adsorption stage of infection and for the duration of the infection.  In 
another experiment, cells were incubated with Sarracenia purpurea extract (SPE).  The 
crude plant extract was supplied in 45% ethanol (EtOH).  An aliquot of extract was 
filtered using a 0.2 μm syringe filter followed by partial EtOH evaporation in a speed 
vacuum for 30 min.  After an adsorption incubation time of 10 min, virus inoculum was 
removed and the cell monolayers were washed with complete medium twice, after which 
complete medium either lacking or containing SPE was added for the duration of the 
infection.   
 
Immunoblot analysis. 
 Cytoplasmic proteins were extracted from virus-infected cells using a modified 
protocol described previously [35].  The protein concentration of each sample was 
determined using the bicinchoninic acid (BCA) assay (Pierce), and 25 μg of protein from 
each sample was analyzed by immunoblotting.  The following primary antibodies were 
used: mouse monoclonal anti-phospho-eIF2α S51 (1:1,000; Epitomics), mouse 
monoclonal anti-eIF2α (1:1,000; Santa Cruz), mouse anti-phospho PKR T446 (1:1,000; 
Epitomics), mouse monoclonal anti-PKR N-terminus (1:1,000; Epitomics), mouse 
monoclonal anti-E3L antibody (1:1,000; a gift from Dr. Stuart Isaacs, School of 
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Medicine, University of Pennsylvania) [38], or mouse monoclonal  anti-HA antiserum 
(1:1,000; Sigma Aldrich).  Either horseradish peroxidase (HRP) conjugated-goat anti-
rabbit immunoglobulin G (IgG) (1:10,000; Calbiochem) or HRP-conjugated goat-anti-
mouse IgG (1:10,000; Fischer Scientific) was used for secondary antibodies.  
Immunoblots were developed using SuperSignal West chemilluminescence reagents per 
the manufacturer’s directions (Pierce) followed by detection by the application of X-ray 
film (Kodak).  The X-ray films were scanned digitally scanned, and the signal intensity of 
each band was quantified using Photoshop pixel intensities followed by the normalization 
of each band to mock-infected (UN) samples. 
 
Gel electromobility shift assays of nuclear-extracted proteins.  
The method for isolating nuclear proteins from virus-infected cells, and assaying 
proteins for the presence of NF-κB was previously described [7].  Briefly, five 
micrograms (RK13) or two micrograms (HeLa) of each extract was incubated with 0.35 
pmol of 32P-labeled double-stranded oligonucleotide probe in Gel Shift Assay System 
Binding buffer (Promega) as per manufacturer’s directions.  Oligonucleotides containing 
the rabbit MMP-9 promoter (5’-CCCCGGTGGAATTCCCCAAATCCT-3’) and (5’-
AGGATTTGGGGAATTCCACCGGGG-3’) were annealed and the resultant double-
stranded oligonucleotide was used as a probe for nuclear extracts from RK13 infected 
cells [21].  Oligonucleotides containing the human TLR2 promoter NF-κB binding site 
(5′-AGTAGATCTCGGACATACGGACATCTGTGCAGAG-3′) and (5′-
AGCTAAGCTTTGGGAGAACTCCGAGCAGTCAC-3′) were annealed and the 
resultant double-stranded oligonucleotide was used as a probe for nuclear extracts from 
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HeLa cells [21].  Some reactions also included 1 μl monoclonal anti-p65 antiserum.  
Reactions were electrophoretically separated in a 6% acrylamide gel (Invitrogen) under 
non-denaturing conditions.  Images of dried gels were analyzed by using the ImageGauge 
and ImageReader programs, respectively (Fuji).  The intensities of the bands were 
quantified using Photoshop pixel intensities, and band intensities were normalized to 
mock-infected (UN) samples. 
 
Reverse transcriptase PCR.  
RK13 cellular monolayers were either mock-infected or infected with WR in the 
absence or presence of SPE (see above).  Total RNA was harvested from infected cells 
using the Qiagen RNeasy kit per manufacturer’s instructions.  A portion of total RNA 
was reverse transcribed into single-stranded cDNA with ImProm-II Reverse 
Transcriptase (Promega) and oligo (dT) primers.  Amplifications of E3L and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA were performed in parallel 
by using PCR and primers specific for the VV E3L gene and rabbit (RK13) GAPDH 
gene.  Primers for VV E3L were (5’-GCAGAGATTGTGTGTGCGGCTATT-3’) and (5’-
GGTGACAGGGTTAGCATCTTTCCA-3’), yielding a 326-bp product.  PCR conditions 
were 95°C for 30 s, 60°C for 45 s, and 72°C for 30 s for 25 cycles.  Primers for rabbit 
GAPDH were (5’-CAAGCCTCTAGCCCACGTA-3’) and (5’-
GGCAATGATCCCAAAGTAG-3’), yielding a 438-bp product [35].  PCR conditions 
were 95°C for 30 s, 62°C for 45 s, and 72°C for 30 s for 25 cycles.  An aliquot of each 
PCR reaction was subjected to agarose gel electrophoresis and amplicons were visualized 
by ethidium bromide staining.   
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Transfection of RNA isolated from virus-infected cells. 
 RK13 and HeLa cellular monolayers were mock-infected or infected as described 
above.  For some experiments, cellular monolayers were treated with Ara C as described 
above.  At the times indicated post-infection (pi), cells were lysed and total RNA was 
isolated using Trizol (Invitrogen) according to the manufacturer’s directions.  Next, DNA 
was removed from each sample using the Turbo DNA-free system (Applied Biosystems).  
Total RNA was quantified and HeLa cells were transfected with either 3 μg (HeLa) or 5 
μg (RK13) of RNA using Lipofectamine 2000 (Invitrogen).  At 6 h post-transfection, 
cells were harvested and lysed in CE buffer, and lysates were analyzed by 
immunoblotting as described above.  In some reactions, RNA preparations were 
incubated with RNases prior to transfections.  Here, 3 μg (HeLa) or 5 μg (RK13) of RNA 
the preparations were incubated for 1 h at room temperature in either buffer alone or 
buffer containing (i) 0.6 U RNase V1 (Ambion) or  (ii) 6 ng RNase A (Ambion) plus 6 U 
RNase T1 (Ambion).  The RNA preparations were transfected into sub-confluent HeLa 
cell monolayers and cells were incubated for 6 h after which total cellular RNA was 
harvested and analyzed by immunoblotting (described above). 
 
Ectopic expression of K1.  
Sub-confluent HeLa cell monolayers were transfected with either 2 μg pCI or 
pK1L using Lipofectamine 2000.  At 18 h post-transfection, cells were either mock-
transfected or transfected with poly I:C (Sigma Aldrich) or 3 μg of RNA isolated from 
S2C#2- or S2C#3-infected cells.  At 6 h post-transfection, cytoplasmic proteins were 
harvested and evaluated by immunoblotting (as described above) for PKR activation. 
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Immunofluorescence microscopy.  
HeLa cells grown on glass cover slips (Fisher Scientific) were mock-infected or 
infected with either vC7L-K1L+ or S2C#2 (MOI = 10).  At 3 h pi, cell monolayers were 
fixed in a 3% paraformaldehyde solution (Fisher Scientific) and then permeabilized with 
a 0.1% saponin solution (Sigma Aldrich).  The treated monolayers were incubated in 
blocking buffer [3% bovine serum albumin (BSA) in PBS] for 1 hour and then incubated 
in blocking buffer alone or blocking buffer containing mouse monoclonal anti-double 
stranded RNA (J2) antibody (1:1,000; English and Scientific Consulting).  After 1 hour, 
monolayers were washed with blocking buffer and subsequently incubated for 1 hour in 
blocking buffer containing biotin-conjugated goat anti-mouse antibody (1:200; Jackson 
Immuno Research).  After washing as above, the monolayers were incubated in blocking 
buffer containing streptavidin conjugated to Alexa Fluor 594 antibody (1:200; Molecular 
Probes).  After 20 min, the monolayers were washed and incubated in a solution 
containing 4’, 6-diamidino-2-phenylindole (DAPI) (1:1,1000; Molecular Probes) for 10 
min.  Finally, monolayers were washed with PBS and mounted on microscope slides 
using hydromount (National Diagnostics).  All incubations proceeded at room 
temperature.  Images were acquired by using the Olympus BX51 immunofluorescence 
microscope, using the 40X objective.  Intracellular fluorescent particles were detected 
and counted using Image J software.  Using slides prepared in triplicate, 50 cells per slide 
were analyzed for the number of cells that possessed one or more fluorescent particles.  
The number of fluorescing cells per slide was tallied and the average was determined.  
Results were recorded in graph form. 
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Detection of viral dsRNA using RT-PCR. 
 Confluent RK13 cellular monolayers were either mock-infected or infected with 
either WR or ΔK1L in the presence of Ara C (described above).  Total RNA was isolated 
from infected cells using the Qiagen RNeasy kit and contaminating DNA was removed 
using the Turbo DNA-free DNase kit (Ambion) according to manufacturers’ instructions.  
Two μg RNA from each sample were incubated for 1 h at room temperature in buffer 
alone or buffer containing (i) 2 μl RNase A/T1 cocktail (Ambion) or (ii) 2 μl RNase A/T1 
cocktail and 0.6 U RNase V1 (Ambion) for a total volume of 20 μl.  Following digestion, 
RNA was purified using a Zymo Research Clean and Concentrator column according to 
manufacturer’s directions.  Prior to reverse transcription, RNA samples were incubated at 
95°C for 5 minutes to denature dsRNA.  One μl of RNA in a 20 μl reaction mixture was 
reverse transcribed into single-stranded cDNA with ImProm-II Reverse Transcriptase 
(Promega) and a specific primer.  The reverse transcription primer for amplification of 
A4L-A5R region was (5’-CGTCTAGTATAGCGTCG-3’), and the reverse transcription 
primer for amplification of the A46R-A47L region was (5’-CATTGTGTTACAGAATC-
3’).  PCR amplifications of the A4L-A5R and A46R-A47L cDNA were performed by 
using PCR with primers specific for these two regions of interest.  Primers for VV A4L-
A5R region were (5’-ATGGCAGACACAGACG-3)’ and (5’-
AGCGTCGTTTAAGAGCAG-3’), yielding a 217-bp product.  PCR conditions were 
95°C for 30 s, 51°C for 45 s, and 72°C for 30 s for 30 cycles.  Primers for VV A46R-
A47RL region were (5’-CAGGGAAACGGATGTATA-3’) and (5’-
TGTGTTACAGAATCATATAAGG-3’), yielding a 104-bp product.  PCR conditions 
were 95°C for 30 s, 47°C for 45 s, and 72°C for 30 s for 35 cycles.  A portion of each 
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PCR reaction was subjected to agarose gel electrophoresis and amplicons were visualized 
by ethidium bromide staining. 
 
3) Results 
 
PKR is activated by early gene transcription in RK13 cells. 
We previously showed that a mutant VV lacking a wild-type K1L gene (ΔK1L) 
activates PKR (by virtue of its ability to stimulate eIF2α phosphorylation) in the rabbit 
RK13 cell line.  PKR activation occurs early after infection and despite the simultaneous 
expression of the VV E3 and K3 PKR inhibitory proteins [5, 9, 40].  We hypothesized 
that dsRNA generated from early gene transcription stimulated PKR, and the K1 protein 
would inhibit this trigger of PKR activation.  To test this hypothesis, our initial approach 
was to evaluate virus-induced PKR activation in RK13 cells when infections occurred in 
the presence of treatments known to inhibit either early (SPE) or intermediate and late 
gene (Ara C) transcription. 
In the absence of drug, the K1 protein inhibited virus-induced PKR activation: 
ΔK1L infection activated PKR to a greater extent than WR, as was evidenced by the 
increased intensity of the phosphorylated eIF2α (p-eIF2α) band (Figure 3.1A).  
Densitometry analysis showed that the phosphorylated form of eIF2α in ΔK1L-infected 
cells was increased about 3.5-fold as compared to cells infected with WR.  PKR remained 
inactive in mock-infected cells since no p-eIF2α was detected.  Intermediate and late 
gene transcription is not detected during ΔK1L infection of RK13 cells [32], implying 
that early gene transcription produced PKR-activating dsRNA.  To ensure that 
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transcription of only early genes occurred, infections proceeded in the presence of 
cytosine arabinoside (Ara C), a drug that inhibits intermediate and late gene expression 
indirectly through inhibiting viral genome replication.  P-eIF2α remained present when 
ΔK1L infection proceeded in the presence of Ara C, as would be expected.  p-eIF2α 
levels remained low in WR-infected cells regardless of treatment, presumably because of 
the presence of the VV E3 protein. 
Recently, extracts from the Sarracenia purpurea plant (SPE) were identified to 
allow VV attachment and entry into the host cell, but inhibit early gene transcription 
(personal communication, Dr. Jeff Langland).  RT-PCR was performed using RNA from 
virus-infected cells to demonstrate that SPE inhibited the transcription of a representative 
early gene, E3L.  As shown in Figure 3.1B, there was a ~70% decrease in the VV E3L 
amplicon intensity when WR infections occurred in the presence of SPE versus the 
absence of SPE.  Accordingly, E3 proteins, as measured by immunoblotting, were not 
detected when infections occurred in the presence of SPE (Figure 3.1A).  SPE 
specifically inhibited viral gene transcription because SPE treatment did not alter the 
amount of cellular GAPDH transcripts.  When SPE was present during infection, eIF2α 
phosphorylation in ΔK1L-infected cells was no longer detected (Figure 3.1A), implying 
that early gene transcription stimulated PKR activation.  As would be expected, the 
presence of SPE did not induce eIF2α phosphorylation in cells that were either mock-
infected or infected with WR.  Unmodified eIF2α proteins were present in similar 
amounts in each sample, ruling out the possibility that differences in the phospho-eIF2α 
levels are due to uneven protein loading.   
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dsRNA isolated from infected RK13 cells possesses PKR activating properties. 
The above studies established that an event associated with viral early gene 
transcription activated PKR in RK13 cells.  We hypothesized that viral early gene 
transcription produced dsRNA capable of activating PKR.  To test this, the PKR 
stimulatory property of RNA extracted from VV-infected cells was evaluated.  RNA 
isolated from virus-infected RK13 cells was transfected into HeLa cells and the 
transfected cell lysates were evaluated by immunoblotting for the ability of the 
transfected RNA to activate PKR (phospho-PKR).  As shown in Figure 3.2A, RNA from 
uninfected RK13 cells did not stimulate PKR.  In contrast, RNA harvested from WR-
infected RK13 cells at late times post-infection (8 h) activated PKR.  This result was 
expected because intermediate and late gene transcription has occurred, producing 
dsRNA and resulting in a 15-fold induction in PKR activation in comparison to RNA 
from uninfected cells.  RNA from WR-infected cells harvested at early times (3 h) post-
infection also stimulated PKR activation, but at a lower level (6-fold).  Such PKR 
activating function was likely due to intermediate gene transcription since phospho-PKR 
was not detected when using RNA isolated from cells infected with WR in the presence 
of Ara C.  RNA from ΔK1L-infected cells (3 h post-infection) retained their PKR 
activating properties when infections occurred in the absence or presence of Ara C, 
implying that early gene transcripts formed dsRNA molecules.  Since no intermediate or 
late genes are transcribed in ΔK1L-infected RK13 cells, RNA harvested at 8 hours post-
infected did not possess abundant PKR activating capacity.  One concern was that PKR 
activation was due to proteins synthesized from transfected viral RNA.  To address this 
possibility, the same immunoblots from Fig. 3.2A were evaluated for the presence of two 
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VV proteins (E3 and K1).  Neither protein was detected, indicating viral proteins were 
likely not synthesized from transfected RNA (data not shown).   
To identify whether dsRNA mediated PKR activation, we repeated the above 
transfection assays using RNA that was incubated with RNases to degrade either single-
stranded RNA (ssRNA; RNase A/T1) or dsRNA (RNase V1) prior to transfection.  The 
same RNA samples used in Fig. 3.2A were used for experiments in Fig. 3.2B to allow for 
direct comparison of PKR activating activity of RNAs.  Similar to Figure 3.2A, PKR was 
activated when HeLa cells were transfected with RNA isolated from Ara C-treated, 
ΔK1L-infected cells (Fig. 3.2B, lane 7).  The PKR activating property was due to dsRNA 
because phospho-PKR was not detected when RNA from ΔK1L-infected cells was 
incubated with RNase V1 (Figure 3.2B, lane 9).  RNA that was digested with a 
combination of RNases A and T1 activated PKR when transfected into HeLa cells (Fig. 
3.2B, lane 8).  Interestingly, this phospho-PKR band was more intense as compared to 
untreated RNA.  When assaying RNA from WR-infected cells treated with Ara C, very 
little phospho-PKR was detected (Fig. 3.2B, lane 4), consistent with results described in 
Figure 3.2A.  Incubation with RNase A/T1 elicited PKR activation (Fig. 3.2B, lane 5), 
albeit at reduced levels when considered to comparably treated RNA from ΔK1L-infected 
cells (lane 8).  WR RNA treated with RNase V1 did not activate PKR upon transfection 
into HeLa cells. As expected, RNAs from mock-infected cells that were incubated with 
either RNase treatments did not activate PKR.   
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Virus-derived dsRNA is present after early gene transcription. 
The next goal was to demonstrate that viral dsRNA was indeed formed due to the 
hybridization of early gene transcripts.  We utilized RT-PCR to detect dsRNA in infected 
RK13 cells.  At least two regions of the VV early gene transcriptome are capable of 
forming dsRNA of sufficient length to activate PKR [16, 41].  The first region includes 
mRNA from the A4L and A5R early genes (Fig. 3.3A).  These mRNAs are partially 
complimentary because the transcription start site for the leftward-transcribed A4L gene 
occurs 282 bases downstream of the transcription start site of the rightward-transcribed 
A5R gene (Fig. 3.3A) [41].  To evaluate if dsRNA from this region existed in infected 
cells, RNase-digested RNA from virus-infected cells were subjected to RT-PCR, using a 
primer specific to the predicted dsRNA annealing area for reverse transcription (nt 
114,161-114,380).  Resultant cDNA, if present, was PCR amplified.  Most of the A4L 
RNA existed as single-stranded mRNA because RNase A/T1 digestion of RNA greatly 
diminished the A4L-A5R amplicon, implying that there was a diminished amount of 
RNA (Fig. 3.3A).  The addition of RNase V1 to RNA samples eliminated the presence of 
an amplicon, which indicated that the amplification of the A4L-A5R region was due to 
dsRNA, and not to incomplete digestion of RNA.  When using RNA from WR-infected 
cells, an amplicon was detected, indicating that the target RNA was present in RNA 
extracted from virus-infected cells.  Digestion of WR RNA with RNases ablated the 
amplification of cDNA, implying that the A4L and A5R mRNAs did not form duplexes 
in vivo.   
A second event that produces mRNA with complimentary sequences is the 
rightward transcription of the A46R and leftward transcription of the A47L early genes.  
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In this case, the 3’ ends of each transcript overlap with each other about 100 nts [41], and 
could hybridize to form dsRNA.  Similar to above, RNA from WR or ΔK1L- infected 
cells yielded PCR products of the appropriate size (~ 100 bp; Fig. 3.3B), indicating that 
the target RNA was indeed present in RNA extracted from virus-infected cells.  Digestion 
of WR RNA with RNases ablated the amplification of cDNA, implying that the A46R 
and A47L mRNAs remained single-stranded in vivo.  In contrast, an amplicon was 
detected when using RNA from ΔK1L-infected cells digested with RNases A/T1, 
implying that dsRNA was present in RNA extracts.  The addition of RNase V1 to RNA 
samples eliminated the presence of an amplicon, which indicated that the amplification of 
the A46R-A47L region was indeed due to dsRNA, and not to incomplete digestion of 
RNA.  No PCR products were detected when RNA was not reverse transcribed or when 
primers were absent from the PCR reactions, indicating that (i) RNA preparations were 
free from DNA contamination, and (ii) the observed PCR products were not due solely to 
the reverse transcription reactions (date not shown).   
 
PKR is activated by intermediate gene transcription in HeLa cells. 
While the deletion of only the K1L gene results in VV-induced PKR activation in 
RK13 cells, both the K1L and C7L genes must be deleted before VV infection activates 
PKR in HeLa cells [30, 40].  These PKR-activating mutant viruses also have a host-range 
phenotype, in which only early and intermediate genes are transcribed [19, 27].  To 
identify whether early or intermediate gene transcripts activated PKR, cells were infected 
with viruses containing a wild-type K1L gene (vC7L-K1L+) that inhibits PKR activation 
or a mutant K1L gene (S2C#2) that does not prevent PKR activation, under conditions in 
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which either early or intermediate gene transcription was inhibited.  Results are shown in 
Figure 3.4.  In contrast to results in Figure 3.1, Ara C treatment of S2C#2-infected cells 
prevented PKR activation, as measured by PKR phosphorylation, indicating that 
intermediate gene transcripts activated PKR (Figure 3.4).  As would be expected, the 
decrease of early gene transcription by SPE or cordycepin (COR) [15, 6] or early gene 
translation by canavanine (CAN) [6] prevented PKR activation because the virus 
replication cycle was inhibited at an event that preceded intermediate gene transcription 
(Fig. 3.4B).   
 
dsRNA generated by intermediate gene transcription stimulates PKR activation in 
HeLa cells. 
 
We next evaluated the PKR-activating ability of RNA isolated from virus-infected 
HeLa cells (Figure 3.5).  As would be anticipated, RNA isolated from uninfected cells 
did not elicit PKR activation when transfected into HeLa cells (Figure 3.5A).  When 
using RNA extracted from vC7L-K1L+-infected cells, active PKR was detected only 
when using RNA extracted from cells 8 hours post-infection, a time in which 
intermediate and late gene expression occurs.  At this later time, RNA activated PKR 5-
fold above RNA from mock-infected cells.  PKR remained inactive when infections 
proceeded in the presence of Ara C, suggesting that intermediate or late gene transcripts 
possess PKR activating function.  In contrast, RNA isolated from S2C#2-infected cells at 
3 h post-infection activated PKR at least 10-fold above RNA from mock-infected cells, 
implying that the absence of the wild-type K1 protein increased the quantity of dsRNA in 
infected cells.  Ara C treatment of virus-infected cells inhibited PKR activation, 
indicating that early gene transcripts did not stimulate PKR in HeLa cells.  Since S2C#2 
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infection of HeLa cells does not proceed past intermediate gene transcription [19], the 
PKR-activating effects must be due to intermediate gene transcripts.  We observed 
identical results when these same RNA samples were transfected into the human 293T 
cell line (data not shown).  The same immunoblots from Fig. 3.5A were evaluated for the 
presence of the VV E3 and K1 proteins.  Neither viral protein was detected, ruling out 
that viral proteins synthesized from transfected RNA were activating (data not shown).   
We evaluated the effect of RNase digestion on PKR activating function of RNAs 
collected from cells 3 hours post-infection (Figure 3.5B).  As in Figure 3.5A, phospho-
PKR was detected when cells were transfected with RNA isolated from S2C#2-infected 
cells (Figure 3.4B, lane 7).  RNA samples retained their PKR activating property when 
digested with the ssRNA-specific RNAses A and T1 (Fig. 3.4B, lane 8).  However, 
RNase V1 digestion eliminated the PKR activating function (Fig. 3.4B, lane 9), 
indicating that dsRNAs were responsible for activating PKR.  A similar trend was 
observed when analyzing RNA from vC7L-K1L+-infected cells: dsRNA possessed 
modest PKR activation (Fig. 3.4B, lane 5), whereas ssRNA lacked that function (Fig. 
3.4B, lane 6).  No PKR activation was observed when RNA from mock-infected cells 
was used for transfection regardless of RNase treatment prior to transfection (Fig. 3.4B).   
 
dsRNA is detected in infected cells in situ.  
The above assays demonstrated that RNA generated by intermediate gene 
transcription possessed PKR activating properties in HeLa cells.  We sought to identify 
dsRNA in virus-infected HeLa cells in situ as direct evidence that dsRNA was indeed 
present when intermediate gene transcription occurred.  To this end, infected cells were 
 87 
fixed and incubated with an anti-dsRNA antibody.  Immunofluorescence microscopy was 
used to visualize dsRNA-antibody complexes.  While this antibody detected dsRNA from 
virus-infected HeLa cells (Fig. 3.6), it did not identify dsRNA in RK13 cells infected 
with VVs (data not shown).  Infected cells were fixed at 3 hours post-infection, a time at 
which dsRNA from intermediate but not late gene transcription has occurred (Figure 3.5). 
Representative images of mock- or virus-infected HeLa cells are shown in Figure 
3.6A.  A relatively low level of background fluorescence was observed in uninfected 
cells.  In contrast, increased intracellular staining was observed in cells infected with 
vC7L-K1L+, resulting in a fluorescent staining pattern that surrounded the nuclei of 
infected cells.  dsRNA was present in S2C#2-infected HeLa cells, as was evidenced by 
the presence of fluorescence.  In this case, a punctate staining pattern was observed, 
similar to those observed previously in VV-infected cells or in cells transfected with poly 
I:C [39, 31].  For all virus-infected cells, the observed fluorescence was intracellular and 
not due to extracellular debris as non-permeabilized cell controls lacked this pattern of 
staining (data not shown).  Using slides prepared in triplicate, 50 cells per slide were 
analyzed for the number of cells that possessed one or more fluorescent particles.  The 
number of fluorescing cells per slide was tallied and the average was determined (Figure 
3.6B).  A two-fold increase in the number of fluorescent cells was observed when 
comparing S2C#2-infected cells to cells infected vC7L-K1L+.  Interestingly, there were a 
greater number of S2C#2-infected cells with multiple fluorescent particles per cell than 
vC7L-K1L+-infected cells (data not shown).   
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Ectopically expressed VV K1 protein inhibits PKR activation induced by synthetic 
or cell-associated dsRNA. 
 
 The above experiments used a virus infection model to study PKR activation. To 
ascertain whether the K1 protein possessed PKR inhibitory function independent of 
infection, cells were transfected with a K1L-containing plasmid (pK1L), and the ability 
of K1 to inhibit poly I:C-induced PKR activation was evaluated.  Levels of 
phosphorylated or native PKR were determined by immunoblotting. As shown in Figure 
7A, the ectopic expression of K1 correlated with a decrease phospho-PKR levels when 
cells were treated with either 250 or 500 ng poly I:C.  Specifically, phospho-PKR levels 
were diminished by 50% and 25% in K1-expressing cells transfected with 250 or 500 ng 
poly I:C, respectively, in comparison to pCI-transfected cells.  PKR was not activated by 
lower amounts of poly I:C (50 or 100 ng) nor by transfection of cells with either pCI or 
pK1L.  The inhibitory effect of the K1 protein was lost when cells were transfected with 
1 μg (Fig. 3.7A) or 3 μg poly I:C (Fig. 3.7B), indicating that the K1 effect could be 
overcome.  PKR protein production remained unchanged in all samples, indicating that 
the changes in phospho-PKR levels were not due to varying amounts of PKR.  Ectopic 
K1 proteins also inhibited PKR activation induced by RNAs extracted from VV-infected 
cells.  Specifically, when RNA from a virus known to activate PKR (S2C#2) was used 
for transfection, phospho-PKR was decreased in pK1L-transfected cells (Figure 3.7B).  
Importantly, RNA from cells infected with a virus known to inhibit PKR activation 
(S2C#3) did not stimulate PKR in the presence or absence of K1 (Fig. 3.7B).  As 
anticipated, RNAs from mock-infected HeLa cells did not elicit PKR activation when 
transfected regardless of whether K1 was present.  
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The VV K1 protein is required to inhibit virus-induced NF-κB nuclear translocation 
in RK13 cells.   
 
PKR mediates several anti-viral effects, including NF-κB activation.  Since the 
K1 protein was reported to inhibit both PKR and NF-κB activation [35, 40], we 
hypothesized that K1’s ability to inhibit NF-κB activation was due to its PKR inhibitory 
function.  In support of this hypothesis, we observed that mutant VVs that no longer 
inhibit PKR activation [40] also did not prevent NF-κB activation (Figure 3.8).  For 
example, ΔK1L infection stimulates PKR while WR infection of RK13 cells does not 
[40].  When assaying nuclear proteins from RK13 cells to detect NF-κB nuclear 
translocation as a measure of NF-κB activation, we observed that ∆K1L infection 
activated NF-κB (Figure 3.8A, lanes 2-4).  NF-κB activation occurred early in the virus 
replication cycle and activation was sustained over the times tested, with the intensity of 
the NF-κB-containing band increased from 18- to 28-fold as infections proceeded.  Using 
nuclear extracts from cells infected with a wild-type VV (WR), this band was less intense 
as infections proceeded, and NF-κB activation was at least 4-fold lower than values from 
ΔK1L-infected cells at all times (Fig. 3.8A, lanes 5-7).  The ankyrin repeat 2 (ANK2) of 
the K1 protein possesses PKR inhibitory function [40].  It was reported that viruses S2N, 
S2C#2 and S2C activated PKR, while S2C#3 or vC7L-K1L+ infection prevented PKR 
activation in RK13 cells.  We observed here that viruses S2N, S2C, and S2C#2 
stimulated NF-κB at least two-fold above infected cells expressing a wild-type K1 protein 
(Figs. 3.8B and C).  Virus S2C#3 virus prevented NF-κB activation (Fig. 3.8B).  Extracts 
from cells treated with PMA, a known activator of NF-κB, produced a band with mobility 
similar to that observed with S2C#2- or S2N-infected cells (Fig. 3.8B); this band 
disappeared when an anti-NF-κB antibody (anti-p65) was added to this reaction, 
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verifying that NF-κB was present in the band.  In HeLa cells, the same trend was 
observed (Fig. 3.9A).  NF-κB activation occurred when cells were infected with VVs that 
allow PKR activation (S2C#2, S2C).  When cells were infected with vC7L-K1L+, S2C#3 
or S2N, NF-κB remained inactive, comparable to the state observed with uninfected cells.   
 
The PKR protein is necessary to activate NF-κB in VV-infected cells. 
To directly test the hypothesis that K1’s inhibition of PKR also was its 
mechanism to inhibit NF-κB activation, we evaluated virus-induced NF-κB nuclear 
translocation in HeLa cells in which >95% of PKR protein expression is stably silenced 
[43].  As shown in Figure 3.9B, infection of either wild-type HeLa cells or PKRkd cells 
with the parental vC7L-K1L+ resulted in low levels of NF-κB nuclear translocation, 
similar to that of uninfected HeLa or PKRkd cells.  Infection of HeLa cells with either 
S2C or S2C#2 stimulated NF-κB activation approximately 2.5 fold above that of 
uninfected cells.  However, when PKRkd cells were infected with either S2C#2 or S2C 
viruses, NF-κB activation was no longer observed, implying that PKR proteins were 
required for virus-mediated NF-κB nuclear translocation.  Importantly, robust NF-κB 
activation was observed when PKRkd cells were treated with either tumor necrosis factor 
(TNF) or phorbol 12-myristate 13-acetate (PMA), demonstrating that the general NF-κB 
activation pathways were functional in this cell line (data not shown). 
 
4) Discussion 
Historically, the identification of viral mechanisms important for replication 
unearthed important inherent anti-viral cellular proteins.  For example, PKR was 
 91 
discovered when it was observed that interferon treatment of VV-infected cells restricted 
the translation of viral mRNAs.  Here, we report that PKR is also stimulated by dsRNA 
formed from poxviral early gene transcripts (RK13 cells) or intermediate gene transcripts 
(HeLa cells).  Under either condition, the presence of the K1 protein correlated with 
reduced dsRNA levels and PKR inhibition.  Our data expand the current view of PKR 
activation during a poxvirus infection.  Previously it was thought that only intermediate 
and late gene transcripts formed dsRNA to activate PKR, with the E3 or K3 proteins 
preventing PKR activation.  We now propose that (i) early gene transcripts also possessed 
PKR activating properties, and (ii) the K1 protein inhibited PKR activation when PKR 
was induced by dsRNA formed from either early or intermediate gene transcripts. 
We identified that dsRNA formed by poxviral early gene transcripts activated 
PKR in the RK13 cell line: PKR activation required the transcription, but not translation, 
of early genes in ΔK1L-infected RK13 cells.  Viral dsRNAs were responsible for PKR 
activation because RNA treated with RNase V1 lost PKR activating function.  
Importantly, two regions of viral dsRNAs were detected in virus-infected cells; the 
intergenic region of A46R-A47L and the intergenic region shared between A4L and 
A5R.  mRNAs transcribed from early genes were thought to have homogenous ends due 
to the presence of the transcription termination sequence UUUUUNU in early viral 
mRNAs [37, 42].  Thus, early gene transcripts were not expected to form dsRNA nor 
stimulate PKR.  Interestingly, it has been reported that transcripts with a single 
termination sequence are terminated with an efficiency rate of 80% [14], implying that 
the 3’ ends of early mRNA are not as homogenous as once believed.  Thus, dsRNA other 
than those detected here also may be generated during VV infection.  In addition to 
 92 
dsRNA formed by complimentary mRNA, deep RNA sequencing of the VV 
transcriptome identified the presence of small antisense transcripts [41].  As PKR 
requires a minimum of 30 nucleotides of dsRNA for activation, binding of these small 
antisense transcripts to viral mRNAs could also result in formation of dsRNA and induce 
PKR activation [41, 33].   
In contrast to infection of RK13 cells, PKR-activating dsRNA was formed during 
poxviral intermediate gene transcription in HeLa cells.  Notably, Ara C treatment of 
S2C#2-infected cells inhibited PKR activation, identifying either intermediate or late 
gene transcription as the PKR activating function.  Since replication of S2C#2 in HeLa 
cells is blocked after intermediate gene transcription [27, 19], we concluded that 
intermediate mRNA molecules must form dsRNA to induce PKR activation.  In support 
of this, dsRNA was detected by immunofluorescence microscopy in S2C#2-infected 
cells.  It has been reported previously that intermediate mRNA, like late gene transcripts, 
have heterogeneous 3’ ends [2, 25].  More recently, it was shown that intermediate 
mRNA from cells infected with MVA (a replication-deficient VV that lacks a wild-type 
K1L gene) indeed forms dsRNA that possesses PKR activating function [24], agreeing 
with our data. 
It was observed that RNaseA/T1-treated RNA possessed a greater PKR activating 
effect than undigested RNA.  One explanation of this result is that extracted RNA may 
contain complexes of RNA that are partially single-stranded and partially double-
stranded in nature.  This web-like formation, in which only some of the RNA is perfectly 
base-paired as dsRNA, previously has been to form from late gene transcripts [31].  As 
such, it is possible that early gene transcripts may form a similar structure and, upon 
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digestion of single-stranded RNA, the remaining dsRNA would bind to and activate PKR 
more effectively.   
It is curious why early viral gene transcripts possessed PKR stimulating activity 
for infected RK13 cells, but not HeLa cells.  One possibility is that there is a VV protein 
that inhibits dsRNA-induced PKR activation from early gene transcripts in HeLa cells, 
but not in RK13 cells.  The VV K3 protein does not possess PKR inhibitory function in 
human HeLa cells, ruling it out as an effector [3, 22].  The VV C7 protein is also known 
to inhibit PKR activation [1, 30].  However, the recombinant viruses used in our studies 
lack the C7L gene [27], eliminating it as a gene with a possible effect.  A favored model 
for our results involves the host-range effect described previously for K1L-deficient 
viruses.  For example, ΔK1L infection of RK13 cells allows early gene transcription, but 
not translation.  Moreover, these early gene transcripts are detected for longer periods of 
time than transcripts from WR-based infections [32].  We predict that the increased 
stability or presence of viral early transcripts in ΔK1L-infected cells enhances the chance 
of interactions between complementary mRNAs.  For S2C#2-infected HeLa cells, 
replication of S2C#2 is blocked after intermediate gene transcription [19, 27].  Thus, the 
increased presence of intermediate mRNA molecules would trigger dsRNA formation.  In 
support of this model, we found that PKR was activated when cells were infected in the 
presence of cycloheximide, an inhibitor of translation, implying that transcripts from a 
wild-type VV infection can activate PKR similar to what is observed in a ΔK1L infection 
(data not shown).   Such a model also explains why dsRNA is increased in cells infected 
with VVs that do not prevent PKR activation (ΔK1L or S2C#2) versus viruses that 
contain wild-type K1L genes (WR or vC7L-K1L+).   
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Many viruses express multiple proteins to inhibit PKR activation.  For example, 
VV encodes at least 4 PKR inhibitory proteins (K1, E3, K3 and C7).  How the K1 protein 
inhibits PKR activation is a future direction of investigation.  One possibility is that the 
K1 protein inhibits dsRNA-PKR interactions because it prevented poly I:C-induced PKR 
activation when expressed ectopically.  It has been shown that the K1 and E3 proteins do 
not functionally substitute for each other.  Thus, K1 may also possess a second PKR-
inhibitory mechanism that is distinct from E3 (dsRNA or PKR binding).  We observed 
here that that the K1 protein inhibits PKR activation induced by either early or 
intermediate transcripts.  It has also been reported that the K1 protein can rescue late gene 
expression in MVA-infected cells [1].  These reports suggest that the K1 protein may use 
a mechanism common for all functions, perhaps by stimulating translation.   
Activated PKR is best known as mediating eIF2α phosphorylation during virus 
infection and has been shown to activate NF-κB during poxvirus infection 23, [26, 29].  
For example, an attenuated strain of VV, MVA, must stimulate PKR to activate NF-κB 
[26].  Moreover, over-expression of PKR in poxvirus-infected cells results in NF-κB 
activation [17, 18].  The K1 protein was reported to inhibit both PKR and NF-κB 
activation [35, 40].  Thus, we hypothesized that PKR inhibition by the K1 protein was 
responsible for the K1 ability to inhibit NF-κB activity [35].  Using a HeLa cell line in 
which most of PKR is absent, we found that virus-induced NF-κB activation no longer 
occurred in PKR-deficient cells, in support of our hypothesis.  At least two other poxvirus 
proteins, CP77 and E3, possess the dual function of inhibiting PKR and NF-κB activation 
[18].  E3, which binds to dsRNA or PKR, also inhibits NF-κB activation by preventing 
PKR activity in VV-infected cells [43].  In contrast, the CP77 protein likely possesses 
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two distinct mechanisms to inhibit PKR and NF-κB activation:  CP77 binds to the p65 
subunit of NF-κB via both N-terminal ANK repeats and an F-box like domain in the C-
terminal portion of CP77 [11, 19, 32].  While K1 is homologous to CP77 due to the 
presence of ankyrin repeats, K1 possesses no apparent F-box sequence [32].   
In summary, this study demonstrates a previously unappreciated role of early 
mRNA for PKR activation.  Moreover, we found that the K1 protein can inhibit PKR 
activation triggered by either early or intermediate gene transcripts.  By inhibiting PKR, 
the VV K1 protein inhibits the downstream signaling pathways such as NF-κB.  Deletion 
of other VV host-range proteins that inhibit PKR, such as E3, have yielded vaccine 
strains that were both effective at eliciting an immune response and less pathogenic; the 
ultimate goal of vaccine development [20].  K1L-deficient viruses or viruses devoid of 
both E3L and K1L may prove to have similar or superior vaccine properties.   
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5) Figures 
  
Figure 3.1 Virus-induced PKR activation in the presence of SPE or Ara C.  RK13 
cellular monolayers were mock-infected (UN) or incubated with either WR or ΔKIL 
(MOI=10) in medium lacking or containing Sarracenia pupurea extract (SPE) or Ara C.  
At 3 h pi, cells were harvested and lysed.  (A) 25 μg of cytoplasmic proteins from each 
sample were analysed by immunoblotting.  Immunoblots (IB) were incubated with 
antibodies to detect phosphorylated eIF2α (p-eIF2α) or unmodified eIF2α.  The same 
immunoblots were incubated with antiserum specific for the vaccinia virus E3 protein 
(E3).  Molecular weight markers (MW) are indicated.  A representative immunoblot is 
shown here.  Densitometry analysis was performed to quantitate the p-eIF2α levels in the 
immunoblot.  The signal from the lane containing lysates from untreated, mock-infected 
(UN) cells was set as a value equal to one.  The amount of p-eIF2α in lanes containing 
lysates from infected cells was graphically represented as a fold-increase above that 
observed for mock-infected cells.  (B) Total RNA was isolated from each lysate and was 
subjected to reverse transcription PCR for E3 and GAPDH mRNA.  The resultant 
amplicons were separated by electrophoresis in a 1% agarose gel and visualized with 
ethidium bromide.  As a negative control, no template (NT) was used for PCR reactions 
with E3 and GAPDH primers.    
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Figure 3.2 PKR activating effects of RNA from virus-infected cells.  RK13 cellular 
monolayers were incubated in medium lacking (-) or containing Ara C (40 μg/ml), and 
were either mock-infected (UN) or infected with either WR or ΔK1L (MOI = 10).  At the 
indicated times post-infection, cells were harvested and lysed.  Total RNA was extracted 
and incubated with DNase.  Five μg RNA was either (A and B) incubated in buffer alone 
or (B) in buffer containing either RNase A and RNase T1 (A/T1) or RNase V1 (V1).  
HeLa cells were transfected with RNA reactions using Lipofectamine 2000.  At 6 h post-
transfection, cells were harvested and lysed, and 25 μg of cytoplasmic protein was 
analysed by using immunoblotting.  Immunoblots (IB) were incubated with antibodies 
against phosphorylated PKR (p-PKR) or unmodified PKR.  Molecular weight markers 
(MW) are indicated.  Densitometry analysis was performed to quantitate the p-PKR 
levels in each immunoblot.  The signal from the lane containing lysates from cells 
transfected with RNA from mock-infected (UN) cells was set as a value equal to one.  
The amount of p-PKR in lanes containing lysates from cells transfected with RNA from 
virus-infected cells was graphically represented as a fold-increase above that observed for 
mock-infected cells.  
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Figure 3.3 Detection of early viral dsRNA using RT-PCR. 
RK13 cellular monolayers were mock-infected (UN) or infected with either WR or ΔK1L 
(MOI=10) in the presence of Ara C (40 μg/ml).  At 2 h pi, cells were harvested and lysed.  
Total RNA was isolated from each lysate and contaminating DNA was removed.  Two μg 
of RNA from each sample were incubated either in buffer alone (-) or buffer containing 
RNase A/T1 or RNase A/T1/V1 for 1 h.  RNA was reverse transcribed using primers that 
specifically annealed to RNA present in the predicted overlapping regions for either (A) 
A4L and A5R or (B) A46R and A47L.  Resultant cDNA was PCR amplified, and a 
portion of each reaction separated by electrophoresis in a 2% agarose gel and visualized 
with ethidium bromide staining. The effect of RNA isolated from virus-infected cells on 
PKR activation in HeLa cells. 
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Figure 3.4 The effect of Ara C, canavanine, or cordycepin on virus-induced PKR 
activation in HeLa cells.  HeLa cellular monolayers were incubated in medium lacking 
(-) or containing (A) canavanine (CAN; 100 mM),  cordycepin (COR; 40 μg/ml), or Ara 
C (40 μg/ml), or (B) SPE or COR.  Cells were mock-infected (UN) or infected with either 
vC7L-K1L+ or S2C#2 (MOI = 10).  At 4 h pi, cells were lysed and 25 μg of protein from 
each sample was analyzed by immunoblotting.  Immunoblots (IB) were probed with 
antibodies recognizing the phosphorylated form of PKR (p-PKR), and then re-probed 
with antibodies recognizing the unmodified form of PKR (PKR).  The same immunoblot 
was incubated with antibodies recognizing the VV E3 protein.  Molecular weight markers 
(MW) are indicated. 
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Figure 3.5 The PKR activating effect of RNA isolated from virus-infected HeLa 
cells.  HeLa cellular monolayers were incubated in medium lacking (-) or containing Ara 
C (40 μg/ml), and cells were mock-infected (UN) or infected with either vC7L-K1L+ or 
S2C#2 (MOI = 10).  At either 3 or 8 h pi, cells were harvested and lysed using Trizol.  
Total RNA from each sample was isolated and treated with DNase.  Three μg RNA was 
(A) transfected into HeLa monolayers, or (B) incubated in buffer alone (-) or in buffer 
containing either RNase A/T1 or RNase V1 for 1 h.  Next, RNA was transfected into 
HeLa cells. At 6 h post-transfection, cells were harvested and lysed, and 25 μg of 
cytoplasmic protein from each sample was analysed by immunoblotting.  Immunoblots 
(IB) were incubated with antibodies against either the phosphorylated (p-PKR) or 
unmodified (PKR) form of PKR.  Molecular weight markers (MW) are indicated.  The p-
PKR levels in each immunoblot were quantitated by densitometry analysis.  The signal 
from the lane containing lysates from cells transfected with RNA from mock-infected 
(UN) cells was set as a value equal to one.  The amount of p-PKR in lanes containing 
lysates from cells transfected with RNA from virus-infected cells was graphically 
represented as a fold-increase above that observed for mock-infected cells. 
 101 
 
 
Figure 3.6 Detection of dsRNA in virus-infected cells in situ.   HeLa cell monolayers 
were either mock-infected (UN) or infected with either vC7L-K1L+ or S2C#2 (MOI = 
10).  At 3 h pi cells were fixed, permeabilized, and incubated with anti-dsRNA antibody, 
followed by incubation with biotin-conjugated goat anti-mouse antibody.  Next, samples 
were incubated with streptavidin-Alexa Fluor 594, followed by incubation in a DAPI-
containing solution.  Cells were examined using immunofluorescence microscopy (40X 
objective).  (A) Representative fields are shown.  (B) Using images from slides prepared 
in triplicate, 50 cells per slide were analyzed for the number of cells that possessed at 
least one fluorescent particle (positive staining).  The number of positive cells per 50 
cells counted was tallied and averaged. 
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Figure 3.7 The effect of ectopically expressed K1 on PKR activation.  Subconfluent 
HeLa monolayers were transfected with either the vector backbone (pCI) or HA-K1L 
plasmid (pK1L).  At 18 h post-transfection, cells were mock-transfected (-), (A) 
transfected with the indicated amounts of poly I:C or (B) transfected with 3 μg of either 
poly I:C or RNA isolated from vaccinia-infected HeLa cells.  At 6 h after the final 
transfection, cells were lysed and 25 μg of cytoplasmic proteins from each sample was 
analyzed by immunoblotting.  Immunoblots (IB) were incubated with antibodies specific 
for either phosphorylated PKR (p-PKR) or unmodified PKR.  The same immunoblots 
were incubated with antiserum raised against the HA epitope (HA) to detect HA-K1 
products.  Molecular weight markers (MW) are indicated.  The p-PKR levels in each 
immunoblot were quantitated by densitometry analysis.  The signal from the lane 
containing lysates from vector-transfected cells receiving 0 ng poly I:C RNA was set as a 
value equal to one.  The amount of p-PKR in lanes containing lysates from cells 
transfected with RNA from virus-infected cells was graphically represented as a fold-
increase above that observed for mock-infected cells. 
 
 103 
 
Figure 3.8 NF-κB nuclear translocation during vaccinia infection of RK13 cells.  
RK13 cells were mock-infected (UN) or infected with the indicated vaccinia viruses 
(MOI=10).  Unless otherwise indicated, infected cells were harvested at 4 h pi.  In some 
experiments, a separate set of mock-infected cells was incubated in medium containing 
PMA (50 nM) for 4 h before harvesting.  Cells were lysed and nuclear proteins were 
extracted.  Five g of protein from each sample were incubated with 32P-radiolabelled 
oligonucleotides that contain an NF-κB binding site.  Reactions were analyzed using an 
EMSA.  Gels were dried and radioactivity was detected by phosphorimaging.  Shifted 
bands containing NF-κB are indicated with a (+).  In some reactions, anti-p65 antibody 
was added.  Densitometry analysis was performed to quantitate the NF-κB-containing 
band present in each lane of an imaged gel.  The signal from the lane containing proteins 
from mock-infected cells (UN) was set as a value equal to one.  The amount of NF-κB in 
lanes containing protein from infected cells was graphically represented as a fold-
increase above that observed for mock-infected cells. 
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Figure 3.9 The effect of K1L mutations on NF-κB activation in HeLa cells.  (A and 
B) HeLa cells expressing PKR (HeLa) or (B) lacking PKR (kd) were mock-infected (UN) 
or infected with the indicated viruses (MOI = 10).  Cells were harvested at 4 h pi, unless 
otherwise noted, and nuclear proteins were extracted.  Two μg of protein from each 
sample was incubated with 32P-radiolabelled oligonucleotides containing the promoter of 
the human TLR2 gene.  Reactions were analyzed using an EMSA.  Shifted bands 
containing NF-κB are indicated with a (+).  Where indicated, anti-p65 antibody was 
added to a reaction, and the resulting super-shifted band is indicated by an asterisk. 
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Chapter 4:  Insights into the mechanism by which the VV K1 protein inhibits PKR 
 
 
1) Introduction 
 Activation of PKR by dsRNA induces a wide range of anti-viral activities 
including NF-κB activation and eIF2α phosphorylation [7].  For PKR activation to occur, 
a PKR monomer must bind to dsRNA at one of two N-terminal dsRNA binding motifs 
[5, 19].  Binding to dsRNA induces a conformational change that relieves auto-inhibitory 
interactions between the C and N-termini of the PKR protein.  Once relieved, PKR can 
dimerize and auto-phosphorylate at two critical threonine residues (T446 and T451) 
rendering it an active kinase [6, 30]. 
Given the multitude of anti-viral effects that occur downstream of PKR activation, 
it is not surprising that most viruses encode inhibitors of PKR [7].  The mechanisms of 
action for these inhibitors are diverse and include sequestering of dsRNA, inhibition of 
PKR dimerization, PKR pseudosubstrates or eIF2α phosphatases and degradation of PKR 
[7].  Vaccinia virus encodes at least two PKR inhibitory proteins, in addition to the K1 
protein, E3 and K3.  The E3 protein prevents PKR activation directly by binding to PKR 
and indirectly by binding to dsRNA to inhibit PKR activation [14, 22].  K3 has homology 
to the PKR substrate eIF2α and like E3 binds to PKR directly to prevent its activation [1, 
23].  Thus far, I have shown that the K1 protein inhibits viral dsRNA induced PKR 
activation and downstream events including NF-κB activation and eIF2α phosphorylation 
[28].  The mechanism by which K1 prevents PKR activation induced by dsRNA remains 
to determined. 
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Data presented in Chapter 3 suggest that K1 may use multiple mechanisms to 
inhibit PKR activation since K1 affects both the amount of dsRNA present in infected 
cells as well as PKR activation induced by dsRNA.  Since K1 possesses ANK repeats 
predicted to mediate protein-protein interactions and lacks any obvious dsRNA binding 
motifs, one possible mechanism for K1 inhibition of PKR would be direct binding to 
PKR.  To assess this, I performed immunoprecipitations using lysates from virus infected 
cells.  I found no evidence to suggest K1 reliably interacts directly with PKR. 
An alternative indirect mechanism for K1 inhibition of PKR activation was 
described in Chapter 3.  In this model, shutdown of protein synthesis when a functional 
copy of K1 is lacking would result in the accumulation of viral transcripts capable of 
forming dsRNA.  This dsRNA could then trigger PKR activation.  This model is 
supported by the fact that all tested K1 mutant viruses that do not support replication, also 
fail to inhibit PKR activation.  This chapter details work in support of this model using 
two alternative rabbit cell lines, R9AB and LLC-RK1.  The requirement for K1 was 
assessed in these cell lines in regards to replication and inhibition of eIF2α 
phosphorylation and NF-κB activation.  Further, a panel of mutant K1 viruses in which 
individual ANK repeats were deleted was tested for their ability to inhibit PKR 
phosphorylation.  In support of an indirect model for K1 inhibition of PKR, all mutant 
viruses that did not support replication also failed to inhibit PKR activation.   
Inhibition of PKR activation is dispensable for the host-range function of K1, as 
translation is shut off during a K1L- infection even when PKR activation is blocked.  
Thus, I considered that K1 may be affecting translation using a different mechanism.  
Recent work has highlighted the importance of the kinases Akt and phosphatidylinositol 
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3-kinase (PI3K) during a poxvirus infection.  Akt and PI3K help regulate cell 
proliferation, growth and translation.  As such, activation of this pathway can be 
important for replication of many viruses.  In the case of poxviruses, activation of the 
Akt/PI3K pathway has been shown to be required for virus replication [25, 27, 29].  Since 
this pathway is important for stimulating translation and is required for replication, I 
posited that K1 may affect Akt activation.  I found that there is a slight delay in Akt 
activation when a functional copy of K1 is lacking but that Akt phosphorylation 
ultimately reaches that of a wild-type infection. 
Finally, this chapter includes experimental work examining interactions between 
K1 and the p65 subunit of the NF-κB transcription factor.  While this work was originally 
started prior to finding that K1 inhibits PKR in order to inhibit NF-κB, I have refocused 
my attention on K1-p65 interactions based on a recent publication.  The cowpox virus 
protein CP77, a protein able to complement for K1 in order to support replication and a 
known inhibitor of PKR, was recently shown to bind to p65 [4].  Since CP77 is a 
functional homologue of K1, I hypothesized that it might also bind to p65.  Based on 
immunoprecipiations using lysates from both infected and transfected cells, I found that 
K1 and p65 did interact.  In contrast, forms of K1 that do not inhibit NF-κB activation 
still bind to p65.  Further study is warranted to examine this interaction. 
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2) Materials and Methods 
 
Cells, viruses and plasmids.   
Human cervical carcinoma (HeLa), human embryonic kidney epithelial (293T) 
rabbit kidney epithelial (RK13 or LLC-RK1) or rabbit lung fibroblast (R9AB) cell lines 
were obtained from the American Type Culture Collection.  All cell lines were 
maintained in DMEM containing 10% fetal calf serum (FCS), referred to as complete 
medium.   
The wild-type Western Reserve (WR) and the attenuated modified vaccinia 
Ankara (MVA) strains of vaccinia virus were used in these studies.  Virus MVA/K1L 
virus contains the wild-type K1L ORF and its natural promoter stably inserted into the 
MVA genome [24].  The ΔK1L virus was made by insertion of the Escherichia coli gpt 
gene into the K1L ORF of WR via homologous recombination [24].  WR and ΔK1L and 
were amplified in BSC-1 cells, while MVA-based viruses were amplified in primary 
chicken embryo fibroblasts (Charles Rivers Laboratories). 
Five recombinant viruses containing wild-type or mutated K1L ORFs were used: 
vC7L-K1L+, S2N, S2C, S2C #2 and S2C#3 [18].  These viruses were previously 
described in chapters 2 and 3.  K1 ANK deletion mutants used in this study were a gift 
from Dr.  Yan Xiang (University of Texas-San Antonio) and were constructed using a 
strategy similar to that previously described.  Briefly, K1L genes with deletions of each 
ANK repeat were inserted into the vC7L-K1L- virus via homologous recombination.  
Virus D1 was created by deletion of K1 amino acid residues 29-58, D3 by deletion of 
residues 93-122, D4 by deletion of residues 127-157, D5 by deletion of residues 159-190, 
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D6 by deletion of 193-222 and D7 by deletion of residues 223-277.  In each case the re-
introduced K1L gene had a V5 epitope tag.  Each of these recombinant viruses was 
amplified in Vero cells. 
The HA-K1L plasmid (pK1L) was created by PCR amplification of the K1L gene 
using the plasmid K1L/pLW44 as the template.  A hemaglutinin (HA) epitope tag was 
engineered onto the C-terminus of the K1L gene.  The PCR product containing the K1L 
gene was cloned into plasmid, in which K1L gene expression was under the control of the 
CMV promoter.  The T7-p65 plasmid was a gift from Dr.  Lin-Feng Chen (University of 
Illinois).   
 
Immunoblot analysis.   
Confluent cellular monolayers in 6-well tissue culture dishes were either mock-
infected or infected with the indicated virus at 10 plaque forming units (PFU)/cell.  After 
an adsorption incubation time of 60 min in DMEM containing 2.5% FCS, virus-
containing medium was removed, and infected cell monolayers were incubated in fresh 
complete medium unless otherwise indicated and harvested at the indicated times post-
infection.  In some cases, monolayers were incubated in complete medium containing 
PMA (50 nM) and harvested at 2 hours post-treatment. 
Cytoplasmic proteins were extracted from virus-infected cells using a modified 
protocol described previously [24].  Infected cells were harvested by scraping at the times 
indicated post-infection and cells were collected by centrifugation (30 sec at 14,000 × g).  
Cell pellets were resuspended and lysed in cytoplasmic extraction buffer (CE) that 
contained the HALT protease inhibitor cocktail (Pierce) for 5 minutes at 4°C.  Lysates 
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were briefly centrifuged (30 sec at 14,000 × g) and the resultant supernatants were 
collected and transferred to new microfuge tubes.  The protein concentration of each 
sample was determined using the bicinchoninic acid (BCA) assay (Pierce).  25 μg of 
protein from each sample was mixed with 5× non-reducing lane marker (Thermo 
Scientific) and 2-mercaptoethanol (Fisher Scientific).  Samples were then boiled for 5 
min and proteins were electrophoretically separated by using SDS-12%PAGE.  
Following electrophoresis, proteins were transferred to a polyvinyl difluoride (PVDF) 
membrane (Millipore), and membranes were incubated for 1 h in TBS containing 0.05% 
Tween-20 (TTBS) and 5% non-fat milk (TTBS-M).  Membranes were then incubated at 
4°C overnight in primary antiserum in TTBS-M.  The following primary antibodies were 
used: mouse monoclonal anti-phospho-eIF2α S51 (1:1,000; Epitomics), mouse 
monoclonal anti-eIF2α (1:1,000; Santa Cruz), mouse anti-phospho PKR T446 (1:1,000; 
Epitomics), mouse monoclonal anti-PKR N-terminus (1:1,000; Epitomics), mouse 
monoclonal anti-HA antiserum (1:1,000; Sigma Aldrich), mouse monoclonal anti V5 
(1:1000, Invitrogen) rabbit polyclonal anti-K1 antiserum (1:500), rabbit monoclonal anti-
p65 (1:1,000; Santa Cruz) or rabbit monoclonal anti-phospho-Akt (1:1,1000, Cell 
Signaling).  Immunoblots were washed in TTBS and incubated in TTBS-M containing 
either horseradish peroxidase (HRP) conjugated-goat anti-rabbit immunoglobulin G 
(IgG) (1:10,000; Calbiochem) or HRP-conjugated goat-anti-mouse IgG (1:10,000; 
Fischer Scientific).  Immunoblots were developed using SuperSignal West 
chemilluminescence reagents per the manufacturer’s directions (Pierce).   
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Gel electromobility shift assays (EMSAs) of nuclear-extracted proteins.   
The method for isolating nuclear proteins from virus-infected cells was previously 
described [8].  The protein concentration of each sample was determined using a BCA 
assay (Pierce).  The rabbit MMP-9 promoter sense 5’-
CCCCGGTGGAATTCCCCAAATCCT-3’ and antisense 5’-
AGGATTTGGGGAATTCCACCGGGG-3’ oligonucleotides containing an NF-κB 
binding site were annealed and the resultant double-stranded oligonucleotide was used as 
a probe for R9AB and LLC-RK1 nuclear extracts [2].  2 μl of oligonucleotide probe 
(10μM) was added to 10 μCi of γ-32P ATP (Perkin Elmer) and T4 polynucleotide kinase 
(10 U; Invitrogen) in kinase buffer per manufacturer’s instructions.  Reactions were 
incubated at 37 °C for 10 minutes and then precipitated by adding 1 µl of 0.5M EDTA, 
89 µl of TE, 25 µl 5M NH4-Ac and 250 µl 100% ethanol.  Precipitation was carried out 
overnight at -20 °C.  Labeled oligonucleotide probe was collected by centrifugation (30 
min at 12,000 x g) and washed with 1 volume 1M NH4Ac and 2 volumes 100% ethanol.  
After centrifugation (30 min at 12,000 x g), the pellets were dried under vacuum and 
resuspended in TE.  Five micrograms of each extract was incubated with 0.35 pmol of 
32P-labeled double-stranded oligonucleotide probe in Gel Shift Assay System Binding 
buffer (Promega) as per manufacturer’s directions.  Some reactions included 1 µl 
monoclonal anti-p65 antibodies (Abcam).  After incubation with the probe, reactions 
were electrophoretically separated in a 6% acrylamide gel (Invitrogen) under non-
denaturing conditions, using TBE buffer.  Gels were then dried on filter paper and 
exposed to a phosphorimager plate (Molecular Devices), and images were developed and 
analyzed using the ImageGauge and ImageReader programs, respectively (Fuji).   
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Immunoprecipitation assays.   
For immunoprecipitation (IP) assays to detect K1 interactions with PKR or p65, 
subconfluent monolayers of 293T or HeLa cells in 6-well plates were transfected with the 
following plasmid combinations.  For endogenous PKR, HeLa were transfected with 1 μg 
of either pCI or HA-K1L.  For endogenous p65, 293T cells were transfected with 1 μg of 
either pCI or HA-K1L.  For overexpression of p65, HeLa cells were co-transfected with 1 
μg each of T7-p65 and pCI or 1 μg each of HA-K1L and pCI or 1 μg each of T7-p65 and 
HA-K1L.  For transfection of 293T cells, FuGene 6 transfection reagent (Roche) was 
utilized as per manufacturer’s recommendations.  For transfection of HeLa cells, 
Lipofectamine 2000 (Invitrogen) was utilized as per manufacturer’s instructions.  
Approximately 18 hours post-transfection, cells were harvested by scraping and pelleted 
by centrifugation at 10,000 x g for 30 s.  For experiments in which K1 interactions with 
PKR and p65 were detected in virus infected cells, infections were performed with the 
Cells were lysed in 500 μl RIPA lysis buffer containing HALT protease inhibitors 
(Pierce) and incubated at 4 °C for 20 min followed by centrifugation at 10,000 x g for 10 
min.  Next, supernatents were transferred to fresh tubes and a 50 μl aliquot of each 
clarified lysate was transferred to a new tube containing 5X Laemmli buffer (Pierce) and 
5% 2-mercaptoethanol.  The remaining 450 μl of each sample was incubated with Protein 
G-Sepharose beads (Amersham) that had been previously conjugated with the following 
antibodies: anti-HA (Sigma Aldrich), anti-p65 (Santa Cruz) or anti-PKR (Santa Cruz) as 
per manufacturer’s recommendations.  Samples were rotated overnight at 4 °C and 
briefly centrifuged (1,000 x g for 30 s) to collect the protein-bead conjugates.  Beads 
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were washed 3 times in 500 μl of RIPA lysis buffer and finally resuspended in 30 μl 2X 
Laemmli buffer containing 5% 2-mercaptoethanol.  Clarified lysates and IP samples were 
boiled for 5 min before immunoblotting as detailed above. 
 
Detection of virus replication.   
Confluent monolayers of R9AB or LLC-RK1 cells in 6-well tissue culture plates 
were infected with either MVA, MVA/K1L, WR or ΔK1L using an MOI of 0.01 
PFU/cell.  For MVA and MVA/K1L infections, at 24 hours post-infection supernatents 
were removed and monolayers were fixed using a 1:1 volume mixture of acetone and 
methanol.  Next, monolayers were rinsed with PBS and incubated with primary anti-
vaccinia  antibody (1:1000) in 3% fetal calf serum (FCS) solution for 1 hour at room 
temperature.  Monolayers were rinsed 2 times with PBS and incubated with secondary 
anti-rabbit antibody conjugated to HRP (1:1000) in 3% FCS solution for 45 minutes at 
room temperature.  Finally, monolayers were rinsed 2 times with PBS and incubated with 
a solution containing dianisidine and 0.06% H2O2 overnight at room termperature.  Foci 
of infection were counted the following day.  For WR and ΔK1L infected cells, at 48 
hours post-infection, supernatants were removed from monolayers, and a 20% ethanol 
solution containing 1% crystal violet was added to each well.  After 5 min, the solution 
was removed and plates were air-dried to visualize virus plaques. 
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3) Results 
 
PKR and K1 do not interact during infection or transfection of HeLa cells. 
Previous work demonstrated that the VV K1 protein inhibits phoshorylation of 
PKR.  As K1 possesses protein interaction domains, I predicted that K1 inhibits PKR 
activation by binding to PKR.  Further, I predicted that K1 mutations that affect the 
ability of K1 to inhibit PKR activation should also affect the ability to bind to PKR.  To 
this end I performed immunoprecipitations (IPs) using wild-type and mutant K1 
containing viruses detect PKR-K1 interactions.  Mutant K1 viruses have previously been 
described in chapters 2 and 3.  The parental vC7L-K1L+, which contains a wild-type 
copy of K1, inhibits PKR activation as would be expected.  The S2C#3 and S2N viruses, 
which contain mutant forms of K1, are still able to inhibit PKR activation.  In contrast, 
the S2C#2 and S2C viruses fail to inhibit PKR activation.  I first queried interactions 
between K1 and endogenous PKR during a virus infection, pulling down with an anti-
PKR antibody (Fig.  4.1A).  Importantly, ample K1 protein was detected in the lysates 
from all virus infected cells indicating any differences in interaction are not due to 
difference in the amount of K1 protein.  Equally important, PKR protein was detected in 
all IP lanes indicating PKR protein was efficiently pulled down during 
immunoprecipation.  No K1 protein was pulled down with PKR when lysates from 
vC7L-K1L+ infected HeLa cells were used.  Similarly, no K1 protein was detected using 
lysates S2C#2, S2C#3 or S2C infected cells.   
I next examined K1-PKR interactions using HeLa cells transfected with K1 (Fig. 
4.1B).  In this assay, I used K1 as the bait to pull down PKR (a reverse IP from that 
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described above).  While ample PKR protein was detected in the lysates from either pCI 
or pK1L transfected cells, no PKR was pulled down with K1 in the IP lanes consistent 
with what I observed during a virus infection.  Together I concluded that K1 does not 
interact with PKR either during virus infection or during transfection.   
 
The K1 protein is required for replication in R9AB and LLC-RK1 cell lines. 
 In Chapter 3 I presented an alternative mechanism for K1 inhibition of PKR in 
which shut down of protein synthesis when K1 is absent or mutated, results in 
accumulation of viral mRNAs leading to dsRNA formation and PKR activation.  In 
support of this hypothesis, all forms of K1 tested thus far that fail to support replication, 
and hence translation, also fail to inhibit PKR activation.  To further bolster this model, I 
examined the role of K1 in allowing for a productive infection in two previously untested 
rabbit cells lines; the rabbit lung fibroblast R9AB and rabbit kidney LLC-RK1 cells lines.  
I was particularly interested in testing other rabbit cell lines since the rabbit kidney RK13 
cell line is the only cell line for which K1 is absolutely required for replication [9].   
 I examined replication of viruses lacking or expressing the K1L gene in R9AB 
and LLC-RK1 cells.  Cellular monolayers were infected with MVA, MVA/K1L, WR or 
ΔK1L and virus replication was assayed either by immunostaining with an anti-VV 
antibody (MVA and MVA/K1L) or crystal violet staining of virus plaques (WR and 
ΔK1L).  As demonstrated in Figure 4.2A, areas of clearing indicating virus infection 
were formed during infection with WR but not ΔK1L.  This result indicates that K1 is 
required for replication in R9AB cells.  When R9AB cells were infected with the 
attenuated MVA stain, which lacks K1, no foci were detected.  MVA and MVA-based 
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viruses do not form plaques.  Instead virus infection is detected as foci, using an anti-
vaccinia antibody.  Infection of cells with MVA/K1L results in foci formation indicative 
of a productive infection (Fig. 4.2A).  No such foci are observed in MVA infected 
monolayers.  I concluded that addition of the K1L gene was sufficient to restore 
replication competence of the MVA virus.  Taken together, K1L was required and for 
replication in R9AB cells.   
In LLC-RK1 cells, infection with the WR virus resulted in plaque formation while 
no plaques were observed during infection with ΔK1L (Fig. 4.2B).  This result was 
identical to that observed with R9AB cells.  As anticipated, infection of LLC-RK1 cells 
with MVA did not result in a productive infection, as evidenced by the lack of foci 
formation.  Surprisingly, infection with MVA/K1L did not restore foci formation (Fig. 
4.2B).  Hence, in LLC-RK1 cells, K1L was required but not sufficient for replication, 
indicating another VV gene was necessary for replication in this cell line.  These results 
together confirm that K1 was required for replication in multiple rabbit cell lines, but also 
highlight the different VV factors required for a productive infection in different cell 
lines. 
 
The requirement for K1 in inhibiting eIF2α phosphorylation and NF-κB activation 
in R9AB and LLC-RK1 cells. 
 
 Having established that K1 was required for replication in R9AB and LLC-RK1 
cell lines, I wanted to assess the requirement for K1 in inhibiting eIF2α phosphorylation 
(an indicator of PKR activation) and NF-κB activation.  If K1 was required for inhibition 
of these two events, this result would lend support to the hypothesis that PKR activation 
was the result of translation shut off and accumulation of early viral mRNAs.  To this 
 121 
end, I infected R9AB and LLC-RK1 cells with viruses lacking and containing the K1L 
gene and detected PKR activation by immunoblotting for phospho-eIF2α, and NF-κB 
activation via EMSA.   
Infection of R9AB cells with MVA resulted in eIF2α phosphorylation at 2 hours 
post-infection.  eIF2α phosphorylation was detected until 6 hours post-infection (Fig. 
4.3A),  similar to that observed in MVA-infected RK13 cells (Fig.  2.1B).  Infection of 
R9AB cells with MVA/K1L resulted in complete inhibition of eIF2α phosphorylation, 
indicating that K1 was sufficient to inhibit PKR activation (Fig. 4.3A).  During infection 
with WR, eIF2α phosphorylation was observed at 2 hours post-infection, and gradually 
increased at 4 and 6 hours post-infection.  Infection with ΔK1L resulted in eIF2α 
phosphorylation at all times measured post-infection.  In comparison to WR infection, 
phospho-eIF2α levels were increased at 2 and 4 hours post-infection.  At 6 hours post-
infection, levels of phospho-eIF2α were decreased with respect to WR.  While K1 
inhibition of eIF2α phosphorylation was not as striking at that observed in RK13 cells 
(Fig. 2.1A), K1 still decreased eIF2α phosphorylation during infection with WR.  Total 
eIF2α levels were similar in all lanes, indicating differences in eIF2α phosphorylation 
were not due to variation in protein loading.  Importantly, no phospho-eIF2α was 
observed in mock-infected cells.  Finally, the K1 protein was detected during MVA/K1L 
and WR infections, but not during MVA or ΔK1L infections as expected. 
 As shown in Figure 4.3B, MVA infection of LLC-RK1 cells resulted in eIF2α 
phosphorylation at 2, 4 and 6 hours post-infection, similar to that observed with both 
R9AB and RK13 cells.  No phospho-eIF2α was detected in lysates from MVA/K1L-
infected LLC-RK1 cells.  Increased amounts of phospho-eIF2α were detected during 
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infection of LLC-RK1 cells with ΔK1L in comparison to WR.  This finding is similar to 
that observed in RK13 and R9AB cells.  Importantly, similar levels of total eIF2α were 
observed in all lanes.  As expected, no eIF2α phosphorylation was observed in lysates 
from uninfected cells.  Thus, I concluded that K1 is both required and sufficient to inhibit 
eIF2α phosphorylation in LLC-RK1 and R9AB cells.  This is in contrast to the host-range 
function of K1, in which K1 was required and sufficient to support replication in R9AB 
cells but only required for replication in LLC-RK1 cells. 
 Previous results demonstrated that K1 inhibited PKR as an indirect mechanism to 
to inhibit NF-κB activation (Fig. 3.10).  Thus, I expected that MVA and ΔK1L, which 
failed to inhibit eIF2α phosphorylation in R9AB and LLC-RK1 cells, would also fail to 
inhibit NF-κB activation.  NF-κB activation was assessed at 4 hours post-infection in 
R9AB cells, a time at which ample eIF2α phosphorylation was observed.  As shown in 
Figure 4.4A, no NF-κB activation was observed in uninfected R9AB cells as evidenced 
by the lack of a mobility shifted band.  Treatment of cells with PMA, a drug that activates 
NF-κB, resulted in a shifted complex indicative of NF-κB nuclear translocation.  
Addition of an anti-p65 antibody (PMA + anti-p65) to the reaction caused the 
disappearance of this band, demonstrating that p65 was a component of this mobility-
shifted complex.  NF-κB nuclear translocation was observed using nuclear extracts from 
MVA infected cells.  In contrast, during infection with MVA/K1L, NF-κB activation was 
inhibited.  Surprisingly, NF-κB remained inhibited during infection with ΔK1L, similar 
to results obtained with WR infected cells.  Thus I concluded that K1 inhibition of PKR 
is sufficient to inhibit NF-κB in R9AB cells, but is not required. 
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 Next, the requirement for K1 in inhibiting NF-κB activation was assessed in LLC-
RK1 cells (Fig. 4.4B). As expected, no NF-κB activation was observed in lysates from 
uninfected cells, while treatment with PMA resulted in NF-κB activation.  MVA 
infection of LLC-RK1 cells stimulated potent NF-κB activation at 2, 4 and 6 hours post-
infection.  Reduced NF-κB activation was observed during MVA/K1L infection.  This 
was consistent with previous findings of increased eIF2α phosphorylation during 
infection with MVA in comparison to MVA/K1L.  Similarly, ΔK1L infection resulted in 
NF-κB activation at all times assayed post-infection while no detectable NF-κB 
activation was observed during infection with WR.  Hence, K1 was both required and 
sufficient to inhibit NF-κB activation in LLC-RK1 cells. 
 
ANK repeats 1-4 and 5 are important for inhibition of PKR activation in HeLa cells. 
 Experiments with R9AB and LCC-RK1 cells yielded some unexpected results in 
regards to the requirement and necessity of K1 for replication and inhibition of PKR and 
NF-κB activation.  To continue assessment of the relationship between replication and 
inhibition of PKR activation, mutant viruses containing deletions of each K1 ANK repeat 
were used [18].  Further, these mutants allowed for determination of which ANK repeats 
were important for inhibition of PKR activation.   
 K1 deletion mutants, designated D1, D2, D3, D4, D5, D6 and D7, have been 
previously described [18].  Briefly, mutants were generated by deletion of the 
corresponding ANK repeat, or in the case of D7 the non-ANK containing C-termini of 
the protein, from parental virus vC7L-K1L+.  D2 was not assessed in this experiment as 
ANK2 has already been shown to be required for inhibition of PKR activation (Fig. 2.9). 
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Mutants D1 and D3-D5 were replication deficient in HeLa cells while D6 and D7 
replicated as wild-type [18].  HeLa cells were infected with deletion mutant viruses and 
PKR activation was assayed by immunoblotting (Fig. 4.5).  Infection with non-replicating 
viruses (D1, D3, D4 and D5) resulted in the detection of phospho-PKR.  No phospho-
PKR was observed in lysates from D7 or D6 (data not shown) infected HeLa cells.  
Importantly, no phospho-PKR was detected in uninfected cells or cells infected with 
vC7L-K1L+ as expected.  Lysates from cells infected with S2C#2, a virus unable to 
inhibit PKR activation, resulted in PKR phosphorylation.  Abundant PKR was detected in 
all lanes indicated equal protein loading.  Finally, K1 protein expression was also 
observed for all viruses tested.  The variation in mobility was a result of different 
deletions to the K1 protein. 
 Assessment of K1 deletion mutants revealed that ANK repeats 1-5 are important 
not only for virus replication but also for inhibition of PKR activation, and hence NF-κB 
activation.  This result supports the hypothesis that K1 control of protein synthesis affects 
PKR activation indirectly.  One caveat for interpretation of results is that large deletions 
to the K1 protein may affect stacking of adjacent ANK repeats and destabilize the 
protein.  Hence, it is not possible to say with certainty that ANK repeats 1-5 are directly 
responsible for inhibiting PKR activation. 
 
Determining the role of the K1 protein in activation of Akt. 
 Recent work has focused on the importance of the Akt/PI3K pathway in allowing 
for a productive VV infection [25, 29].  Activation of this pathway stimulates translation 
via assembly of the eIF4F translation initiation complex [10].  Assembly of this complex 
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is inhibited by the negative regulatory protein 4E-BP, which binds to eIF4E, a component 
of the active translation initiation complex.  Phosphorylation of 4E-BP, a downstream 
event of Akt/PI3K activation, releases eIF4E and allows for formation of the active eIF4F 
complex [11].  It is known that VV promotes formation of this complex via inactivation 
of 4E-BP [26].  To determine if K1 stimulates viral translation via activation of this 
process, I examined Akt phosphorylation, a measure of Akt activation, in virus infected 
cells (Fig.  4.6).  In uninfected HeLa cells, low levels of phospho-Akt were detected as 
has been previously reported [25, 29].  During infection with vC7L-K1L+, Akt activation 
was stimulated by 30 minutes post-infection, and it increased to 4 hours post-infection at 
which point it was sustained.  During infection with S2C#2, Akt was initially activated at 
30 minutes post-infection similar to that of vC7L-K1L+.  Full activation was delayed in 
lysates from S2C#2 infected cells in comparison to vC7L-K1L+. Reduced Akt 
phosphorylation was observed at 1 hour post-infection and to a lesser extent at 2 hours 
post-infection.  By 4 hours post-infection Akt activation reached levels similar to that of a 
wild-type infection.  Protein synthesis, both viral and cellular, was almost completely 
shut off by 4 hours post-infection with S2C#2 (Fig. 2.8A).  Thus, despite the delay in Akt 
phosphorylation during infection with S2C#2, it seems unlikely that K1 activation of Akt 
contributes to modulation of translation.   
 
K1 binds to p65 regardless of its ability to inhibit NF-κB activation. 
 Though K1-PKR interactions were not detected, the presence of ANK repeats in 
the K1 protein suggests that K1 binds to another protein.  The cowpox CP77 protein 
functionally replaces K1 to allow for replication in RK13 cells and also inhibits PKR 
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activation [12, 21].  Most recently CP77 was shown to inhibit p65 nuclear translocation 
by binding to p65 via the N-terminus which contains ANK repeats and a C-terminal F-
box like domain.  CP77 inhibition of NF-κB was found to be dispensable for replication 
[4].  Given the similarities between K1 and CP77, I assessed binding between K1 and 
p65 in infected and transfected cells.   
 Lysates from infected 293T cells were immunopreciptated with anti-p65 
conjugated beads to pull down p65 and any associated proteins.  K1 was detected by 
immunoblotting (Fig.  4.7A).  K1-p65 interactions were detected in immunoprecipated 
lysates from WR infected cells.  In contrast, no K1-p65 interactions were 
immunoprecipitated from ΔK1L infected cells.  As expected no K1 was pulled down 
from uninfected cells.  Having established that K1 and p65 interact during an infection, I 
assayed for interactions in transfected cells as further indication of a true interaction (Fig.  
4.7B). Consistent with results obtained using infected cells, K1-p65 interactions were 
detected in lysates from 293T cells transfected with K1.  Hence, p65 interacts with K1 
independent of a virus infection.  No K1-p65 interactions were detected from cells 
transfected with empty vector pCI.  In this assay, no p65 was detected in the lysates from 
either pCI or pK1L transfected cells.  The cause of this is unknown since p65 was readily 
detected in the immunoprecipitation.   
 Having demonstrated interactions between K1 and endogenous p65 in both a 
transfection and an infection, I assessed interactions between K1 and overexpressed p65.  
HeLa cells were transfected with either p65 or pK1L alone or co-transfected with both 
together.  As shown in figure 4.7C, robust K1-p65 interactions were detected in lysates 
from co-transfected cells.  Surprisingly, no K1-p65 interactions were detected from 
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lysates transfected with only K1 as was observed in Figure 4.7B.  This was not due to 
lack of K1 protein expression as K1 was detected in the lysates and also 
immunoprecipitated.  A reduced amount of p65 was detected in immunoprecipitated 
lysates from p65 only transfected cells despite the fact that no K1 was present.  This 
result suggests that p65 may bind non-specifically to the anti-HA-conjugated beads used 
for immunoprecipitation of HA-K1L and interacting proteins.  Increased levels of p65 
were detected in the lysates from p65 transfected as would be expected.  Similarly K1 
was detected in lysates and immunoprecipitates from pK1L transfected cells indicating 
K1 was expressed and efficiently pulled down with the anti-HA beads.  As further proof 
of p65 interaction with K1, I detected p50, a subunit of NF-κB.  A small amount of p50 
immunoprecipitated with p65 in co-transfected cells.   
 Next, I examined p65-K1 interactions in cells infected with the mutant K1 viruses 
used previously (Fig. 4.8).  Anti-p65 conjugated beads were used to immunoprecipitate 
V5-tagged K1 protein.  K1 protein was detected in the lysates from all virus infected cells 
at approximately equal levels with the exception of S2N which had a reduced amount of 
K1.  K1 immunoprecipitation with p65 was detected using lysates from vC7L-K1L+, 
S2C#2, S2C#3 and S2C infected HeLa cells.  No p65-K1 interactions were detected in 
S2N infected cells.  This result was somewhat unexpected.  If K1 inhibition of NF-κB 
activation was dependent upon binding to p65, I anticipated that K1 from S2C#2 and S2C 
viruses would not bind to p65.  Since these mutant forms of K1 bound to p65, this argues 
against this hypothesis.  Further K1 from the S2N virus which inhibits NF-κB activation 
did not bind to p65.  Taken together, K1 binds to p65 but it remains to be determined if 
this binding is relevant for K1 function or represents a non-specific interaction. 
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4) Discussion 
 The VV K1 protein inhibits PKR activation induced by dsRNAs during an 
infection and when ectopically expressed.  K1 also affects the amount of dsRNA present 
in virus infected cells (See Chapters 2 and 3).  Thus, I hypothesized that K1 may inhibit 
PKR activation via 2 different mechanisms.  Since K1 possesses ANK protein interaction 
motifs, it was plausible that K1 could bind directly to PKR in order to inhibit its 
activation.  This is a strategy employed by many viral PKR inhibitory proteins including 
those of VV; E3 and K3 [22, 23].  Data presented in Fig.  4.1 demonstrates that K1-PKR 
interactions were not reliably detected in either infected or transfected cells.   
 Previously, K1 has been shown to bind to several target proteins.  Using a yeast 
two hybrid screen, K1 interactions were detected with the VV C10 protein, a protein of 
unknown function, and the cellular ERK5 protein, a member of the mitogen activated 
protein kinase family [16].  To determine if K1-ERK5 interactions were relevant during 
an infection, I assessed the activation state of ERK5 during an infection and found no 
difference in ERK5 phosphorylation when K1 was present or absent (data not shown).  
Thus, I concluded that this interaction was not important for K1 inhibition of PKR 
activation.  The rabbit homologue of human ACAP2, a GTPase-activating protein for the 
small GTPase ARF6, was also shown to bind to K1.  This interaction was not important 
for the host-range function of K1. Given that there is no cross-talk between ACAP2 and 
the PKR pathway, it is unlikely that this interaction is important for inhibition of PKR 
activation [3, 13, 18].   
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 While K1 binding to PKR is likely not the mechanism by which K1 inhibits PKR 
activation, many other strategies for PKR inhibition have been reported [15].  As K1 
blocks PKR activation, it is unlikely that K1 works downstream of PKR activation, at the 
stage of inhibition of eIF2α phosphorylation, as many inhibitors of this pathway do.  
Though K1 lacks obvious dsRNA binding motifs to prevent PKR activation, I can’t rule 
out the possibility that K1 uses this mechanism of action.  Influenza virus has been 
reported to recruit the cellular chaperone p58, allowing for binding to PKR and inhibition 
of PKR activation [17].  Thus, K1 interaction with cellular inhibitors of PKR including 
p58, Hsp90, Hsp70 or nucleophosmin, should be investigated as a mechanism for 
inhibition [1].   
 Evidence has been presented in this chapter both in support of and in opposition 
to the hypothesis that K1 indirectly inhibits PKR activation.  If a block in protein 
synthesis when K1 is absent or mutated is the cause of PKR activation, all mutant K1 
viruses that fail to replicate should also fail to inhibit PKR activation.  In agreement with 
this, a perfect correlation was found between replication and inhibition of PKR activation 
using all K1 ANK deletion mutants tested (Fig. 4.5).  Further, K1 was shown to be 
required for replication and inhibition of eIF2α phosphorylation in LLC-RK1 and R9AB 
rabbit cell lines (Figs. 4.2 and 4.3).  Assessment of the sufficiency of K1 for replication 
and inhibition of PKR activation yielded a surprising result.  While K1 restored the 
ability of the MVA virus to replicate in R9AB cells, no replication was detected in LLC-
RK1 cells (Fig.  4.2).  Thus, it was anticipated that MVA/K1L would fail to inhibit eIF2α 
phosphorylation in LLC-RK1 cells.  In fact, infection with MVA/K1l resulted in no 
detectable phospho-eIF2α (Fig. 4.3A).  This result contradicts the previously proposed 
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model and argues that K1 inhibits PKR activation directly.  Alternatively, as eIF2α 
phosphorylation is an event downstream of PKR activation, it is possible that PKR is 
activated without phosphorylation of eIF2α.  No commercial antibodies are available that 
recognize the rabbit form of p-PKR (or PKR), making direct detection of PKR difficult.  
As NF-κB activation is detected in MVA/K1L infected LLC-RK1 cells, albeit to a lesser 
extent than that of MVA infected cells, this suggests that PKR could be activated.  
Further characterization of this cell line may yield additional information about the 
function of K1.   
Another notable exception was the observation that no NF-κB activation is 
detected during infection of R9AB cells with ΔK1L despite the fact that PKR is activated.  
In contrast NF-κB is activated during infection with R9AB (Figs. 4.2A and 4.3A).  Since, 
PKR activation signals to activate NF-κB, this result was surprising.  One explanation for 
this data is that another VV protein is able to block PKR induced NF-κB during ΔK1L 
infection of LLC-RK1 cells.  The MVA virus is missing approximately 15% of its 
genome, including ORFs encoding several other NF-κB inhibitory proteins [20].  Hence, 
infection with ΔK1L which encodes other NF-κB inhibitors may be able to block NF-κB 
activation in contrast to infection with MVA.  Further, the R9AB cell line is a lung 
fibroblast line while RK13 and LLC-RK1 lines are kidney epithelial cell lines.  It is 
possible that differences in cell types could explain this result. 
 Results obtained from LLC-RK1 and R9AB cell lines along with ANK deletion 
mutants did not explicitly rule in or out the possibility that K1 inhibits PKR activation 
indirectly.  More evidence in favor of this model would strengthen this hypothesis.  To 
this end, a closer look at the role of K1 in stimulating translation is pertinent.  Though a 
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delay in full Akt phosphorylation was observed during infection with S2C#2, this is 
unlikely to explain the failure of this virus to replicate based on the kinetics of activation 
(Fig. 4.6).  K1 modulation of the phosphatidylinositol 3-kinase pathway and assembly of 
eIF4F translation complex should be further investigated.  As infection with a K1L- virus 
results in stabilization of early viral transcripts, K1 could also play a role in removal and 
degradation of early mRNAs [21].   
 Finally, in this chapter I present evidence in support of K1-p65 interactions.  VV 
proteins interacting with multiple targets, particularly ANK containing proteins, have 
previously been reported [4].  Thus, K1 may interact with a variety of targets.  What 
remains unclear is how this reaction would further inhibit NF-κB activation.  Since (i) 
NF-κB activation is dependent upon PKR activation in virus infected cells and (ii) NF-κB 
activation occurs downstream of PKR activation, the mechanism by which K1-p65 
interactions would contribute to NF-κB inhibition is unknown.  Further, mutations to the 
K1 protein that do not inhibit NF-κB activation still bind to p65.  One possibility is that 
small mutations to the K1 protein might not disrupt binding but would be sufficient to 
alter inhibition.  The relevance of these interactions is being further investigated in the 
Shisler lab. 
 In conclusion, this chapter sheds further light as to the mechanism of action of the 
VV K1 protein.  K1 interactions with PKR were not detected in VV infected cells, ruling 
out the possibility that K1 inhibits PKR by binding to it.  Two additional rabbit cell lines 
were indentified for which K1 was required for replication and inhibition of PKR 
activation.  This result bolsters the hypothesis that K1 could inhibit PKR activation 
indirectly via simulation of translation.  Finally, K1-p65 interactions were detected in 
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virus infected and transfected cells though the relevance of this to a virus infection 
remains to be determined.  Taken together, these results contribute to the overall 
understanding of the mechanism of action of the VV K1 protein and identify areas for 
further exploration. 
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5) Figures 
 
Figure 4.1 K1-PKR interactions in virus infected and transfected cells.  (A) 
Confluent HeLa cell monolayers were infected with the indicated viruses at an MOI of 
10.  At 4 hours post-infection, cellular monolayers were harvested by scraping and lysed 
in RIPA buffer.  An aliquot of each lysate was collected to probe for protein expression.  
The remaining lysate was immunoprecipiated with anti-PKR conjugated IgG beads.  
Immunoprecipitated (IP) and non-immunprecipitated (Lysates) lysates were separated by 
SDS-PAGE, transferred to PVDF membrane and membranes were probed with antiserum 
recognizing either a V5 epitope tag (top panel) or PKR (bottom panel).  Molecular weight 
markers (MW) are indicated.  (B) Subconfluent monolayers were transfected with either 
pCI or pK1L.  At 18 hours post-transfection, cellular monolayers were harvested by 
scraping and lysed in RIPA buffer.  An aliquot of each lysate was collected to probe for 
protein expression.  The remaining lysate was immunoprecipiated with anti-HA 
conjugated IgG beads.  Immunoprecipitated (IP) and non-immunprecipitated (Lysates) 
lysates were separated by SDS-PAGE, transferred to PVDF membrane and membranes 
were probed with antiserum recognizing PKR.  Molecular weight markers (MW) are 
indicated. 
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Figure 4.2 The requirement of K1L in VV infected rabbit R9AB, LLC-RK1 and 
RK13 cells.  Confluent cellular monoloayers of either R9AB or LLC-RK1 or cells were 
infected with the indicated viruses.  Monolayers infected with either WR or ΔK1L were 
incubated for 48 hours.  Post-infection monolayers were incubated with 0.1% crystal 
violet in 20% ethanol solution.  Monolayers infected with either MVA or MVA/K1L 
were fixed in a 1:1 by volume methanol:acetone solution, incubated with primary anti-
VV antibody followed by incubation with secondary anti-rabbit-HRP conjugated 
antibody and finally stained with a dianisidine containing solution. 
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Figure 4.3 eIF2α phosphorylation in virus-infected R9AB and LLC-RK1 cells.  
R9AB (A) and LLC-RK1 (B) cellular monolayers were mock-infected (UN) or infected 
with either WR, ΔK1L, MVA or MVA/K1L at an MOI = 10.  Infections proceeded for 
the indicated time post-infection.  Immunoblots containing cytoplasmically extracted 
proteins were probed with antiserum recognizing either the phosphorylated (top panel) or 
unmodified (bottom panel) form of eIF2α.  Molecular weight markers (MW) are 
indicated. 
 136 
 
 
Figure 4.4 The activation state of NF-κB in R9AB and LLC-RK1 cells.  Either R9AB 
(A) or LLC-RK1 (B) cells were mock-infected or infected with the indicated virus 
(MOI=10) and harvested at the indiciated times post-infection.  In some experiments 
mock-infected cells were incubated in medium containing PMA (50nm) for 4 hours prior 
to harvesting.  Cells were harvested and lysed, and nuclei were collected.  Nuclear 
extracts were incubated with 32P-labeled oligonucleotide probe containing a rabbit NF-κB 
binding site.  Reactions were electrophoretically separated in 6% DNA retardation gels 
under non-denaturing conditions.  Gels were dried and images developed using a 
phophorimager.  Mobility shifted bands are indicated with (+).   
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Figure 4.5 The effect of K1 ANK deletion mutant infection on PKR activation.  HeLa 
cell monolayers were mock-infected (UN) or infected with either vC7L-K1L+, S2C#2, 
D1, D3, D4, D5 or D7 at an MOI of 10.  At 4 h post-infection, cells were harvested, 
prepared for immunoblotting and probed with antiserum recognizing either the 
phosphorylated form of PKR (p-PKR) or the unmodified form.  Molecular weight 
markers (MW) are indicated. 
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Figure 4.6 The activation state of Akt in virus infected HeLa cells.  HeLa cell 
monolayers were mock-infected (UN) or infected with either vC7L-K1L+ or S2C#2 at an 
MOI of 10.  At the indicated time post-infection, cells were harvested, prepared for 
immunoblotting and probed with antiserum recognizing either the phosphorylated form 
of Akt (p-PKR).  Molecular weight markers (MW) are indicated. 
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Figure 4.7 K1-p65 interactions in virus infected and transfected cells. 
(A) Confluent 293T cellular monolayers were either mock infected or infected either WR 
or ΔK1L at an MOI of 10.  At 4 hours post-infection, cellular monolayers were harvested 
by scraping and lysed in RIPA buffer.  An aliquot of each lysate was collected to probe 
for protein expression.  The remaining lysate was immunoprecipiated with anti-p65 
conjugated IgG beads.  Immunoprecipitated (IP) and non-immunprecipitated (Lysates) 
lysates were separated by SDS-PAGE, transferred to PVDF membrane and membranes 
were probed with antiserum recognizing either K1L.  Molecular weight markers (MW) 
are indicated.  (B and C) Subconfluent monolayers were transfected with either pCI or 
pK1L (B) or either p65 or pK1 alone or contransfected with p65 and pK1 (C).  At 18 
hours post-transfection, cellular monolayers were harvested by scraping and lysed in 
RIPA buffer.  An aliquot of each lysate was collected to probe for protein expression.  
The remaining lysate was immunoprecipiated with anti-HA conjugated IgG beads.  
Immunoprecipitated (IP) and non-immunprecipitated (Lysates) lysates were separated by 
SDS-PAGE, transferred to PVDF membrane and membranes were probed with antiserum 
recognizing p65 (B and C-top, K1L (C-middle) or p50 (C-bottom).  Molecular weight 
markers (MW) are indicated.   
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Figure 4.8 The effect of K1 protein mutations on K1-p65 interactions. 
Confluent HeLa cell monolayers were either mock-infected or infected with the indicated 
viruses at an MOI of 10.  At 4 hours post-infection, cellular monolayers were harvested 
by scraping and lysed in RIPA buffer.  An aliquot of each lysate was collected to probe 
for protein expression.  The remaining lysate was immunoprecipiated with anti-p65 
conjugated IgG beads.  Immunoprecipitated (IP) and non-immunprecipitated (Lysates) 
lysates were separated by SDS-PAGE, transferred to PVDF membrane and membranes 
were probed with antiserum recognizing either a V5 epitope tag.  Molecular weight 
markers (MW) are indicated.   
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Chapter 5: Summary of thesis and future directions 
 
1) Summary 
 The VV K1 protein is a potent inhibitor of the anti-viral PKR pathway.  I found 
that K1 was both required and sufficient to inhibit eIF2α phosphorylation, and hence 
PKR activation, in RK13 cells.  Further, PKR activation occurred early during VV 
infection when K1 was absent; a time at which there were no previous reports of PKR 
activation. Using HeLa and RK13 cells, I observed that the 2nd ANK repeat of K1 was 
important for inhibiting PKR activation [15].  Since VV expresses other inhibitors of 
PKR, I wondered what was triggering PKR activation in K1L- infected cells. To this end, 
I found that early (RK13) and intermediate (HeLa) viral double-stranded RNAs activated 
PKR and were present in greater quantities when K1 was absent or mutated. 
Additionally, I found that ectopic expression of K1 inhibited PKR activation.  Together 
these results suggest that K1 may utilize multiple mechanisms to inhibit PKR activation.  
Finally, I found that K1 inhibition of PKR is required for inhibition of NF-κB activation, 
an event downstream of PKR activation, but is dispensable for replication [15].  As K1 
was previously found to be required for both replication and inhibition of NF-κB 
activation, this finding is significant. In summary, my thesis work identified a novel 
function for the VV K1 protein and furthered understanding of poxvirus biology with the 
finding that early dsRNAs are present during a VV infection. 
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2) Future Directions 
Prior to the onset of this thesis research, K1 was classified as a host-range protein 
capable of inhibiting NF-κB activation [9, 11]. Little was known in regards to how K1 
mediated these two functions.  Since the only structural motifs present in K1 are ANK 
repeats, there were no obvious K1 interacting proteins.  This thesis was the first to 
characterize the K1 protein as an inhibitor of PKR activation and extended this finding to 
determine the mechanism by which K1 inhibits NF-κB activation. In the following 
sections, I will address areas of future study in regards to the K1 protein. 
 
The K1 host-range function. 
Determination of the mechanism of the K1 host-range function is one area for 
future investigation.  As replication of ΔK1L is halted at the stage of early viral 
translation, it is reasonable to hypothesize that K1 plays a role in stimulating translation 
[10, 13].  Phosphatidylinositol 3-kinase and Akt pathway activation are critical for viral 
protein synthesis, and hence for a productive infection [12, 16].  The viral protein/s 
responsible for activating this pathway during a VV infection have not been identified.  
Thus, the role of K1 in this pathway should be assessed.  The myxoma virus MT-5 
protein, which like K1 contains ANK repeats, activates Akt and this event is critical for 
virus replication [14].  Though K1 is not responsible for Akt activation, the delay in Akt 
activation during infection with S2C#2 warrants further investigation (Fig. 4.6).  The role 
of K1 in stimulating events downstream of PI3K/Akt activation, such as assembly of the 
eIF4F initiation complex and inactivation of the repressor 4E-BP1, should be determined.   
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As early viral transcripts are aberrantly detected during infected with a K1- virus, 
it is also reasonable to think that K1 may function to remove early viral transcripts [10].  
Since K1 lacks any obvious RNA binding motifs it seems unlikely that it would bind 
directly to viral transcripts.  It is more likely that K1 would bind to another protein, 
cellular or viral, to mediate this event.  As K1 has previously been shown to bind the viral 
C10 protein, this is one possibility [7].  
It is interesting that many host-range proteins inhibit PKR, including K1, E3, C7 and 
CP77.  Only in the case of the E3 protein is inhibition of PKR responsible for replication 
[17].  For K1, C7 and CP77, inhibition of PKR activation is dispensable for the host-
range function [1, 5, 15].  Thus, the hypothesis that K1 inhibits PKR indirectly by 
blocking translation shut off could apply to C7 and CP77 as well.  Determining the 
mechanism of the K1 host-range function would allow for testing of this hypothesis and 
could yield information about 3 different poxvirus proteins. 
 
K1-p65 interactions. 
 Experiments presented in Chapter 4, demonstrated that K1 interacts with the NF-
κB subunit p65. The cowpox CP77 protein binds to p65 and also inhibits PKR activation, 
so this interaction is not without precedent [2, 5].  Detection of K1-p65 interactions was 
somewhat surprising since (i) activation of PKR is required for NF-κB activation and (ii) 
NF-κB activation occurs downstream of PKR activation.  Further, mutant forms of K1 
that do not inhibit PKR activation still bound to p65 (Fig. 4.8).  Since PKR activation is 
directly responsible for NF-κB activation, this result suggests that K1-p65 interactions 
may not be functionally relevant and that K1 may bind non-specifically to p65.  
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Continued study of the K1-p65 interaction is ongoing in the Shisler lab.  To this end, the 
K1L genes from the ANK2 mutant viruses are being sub-cloned into expression vectors 
for further binding studies.  Since immunoprecipitations were the only binding assays 
presented in this thesis work, future studies may utilize more stringent binding assays.  
 
The mechanism of K1 inhibition of PKR. 
This thesis work has suggested that K1 may use multiple mechanisms to inhibit 
PKR activation based on the fact that (i) K1 affects the amount of dsRNA detected in 
virus infected cells and (ii) K1 inhibits PKR activation independent of a virus infection 
(Chapter 3).  While I have presented one hypothesis to explain how K1 could inhibit 
dsRNA accumulation and hence PKR activation, this does not explain how ectopic K1 
expression would inhibit PKR activation induced by synthetic dsRNA or viral dsRNAs.  
Thus, one area for further study is determining the mechanism by which K1 inhibits PKR 
activation independent of a virus infection.   
While K1-PKR interaction is the simplest model to explain inhibition of PKR 
(Fig. 4.1), no K1-PKR interactions were detected.  We also did not detect activation of 
the upstream PKR activator PACT when K1 was absent in VV infected cells (data not 
shown). Thus, it is not likely that K1 binds to an activator of PKR. An alternative 
possibility is that K1 interacts with PKR inhibitory proteins such as p58IPK, glycoprotein 
p67, chaperones Hsp90 and Hsp70 or nucleophosmin (NPM) [3, 4, 6, 8].  K1 interaction 
with a PKR inhibitory protein could stabilize the interaction in order to inhibit PKR 
activation and thus should be investigated in the future. Finally, I can’t rule out the 
possibility that K1 could facilitate removal or degradation of dsRNAs via a direct or 
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indirect mechanism.  This scenario would explain observations that K1 affects both the 
amount of dsRNA present during an infection and can inhibit PKR activation 
independent of an infection and hence future investigation is warranted. 
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